Compositions and methods for the treatment of multiple sclerosis

PrC-210 administration addresses the inadequacies of current MS treatments by reducing relapse severity and duration and suppressing demyelination, offering therapeutic benefits across MS subtypes through targeted dosing strategies.

WO2026236152A1PCT designated stage Publication Date: 2026-11-12OBVIA PHARM LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/026593
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-08-22
Filing Date
2026-05-04
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current treatments for multiple sclerosis (MS) are inadequate in addressing neuroinflammation and oxidative stress, leading to demyelination, axon degeneration, and neuronal dysfunction, with a need for new therapeutic interventions to slow progression and reduce relapse severity.

Method used

Administration of PrC-210, or its pharmaceutically acceptable salts, in various dosages and routes to treat and prevent MS, including intravenous and oral administration during quiescent and non-quiescent periods, targeting different stages of the disease to reduce inflammation and demyelination.

Benefits of technology

PrC-210 effectively reduces relapse severity and duration, extends remission, and suppresses demyelination, providing therapeutic benefits across different MS subtypes.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026026593_12112026_PF_FP_ABST
    Figure US2026026593_12112026_PF_FP_ABST
Patent Text Reader

Abstract

This invention features the use of the aminothiol PrC-210 for treating or preventing multiple sclerosis (MS) and subsets thereof (e.g., prodromal MS, relapsing-remitting MS, primary progressive MS, secondary progressive MS, and progressive relapsing MS) in a subject in need thereof. The invention also provides methods of suppressing demyelination in a subject in need thereof and methods of reducing the frequency or severity of a flare-up period or a relapse period in a subject suffering from multiple sclerosis.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] PATENT

[0002] ATTORNEY DOCKET NO: 51707-007W02

[0003] COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS

[0004] BACKGROUND

[0005] Multiple sclerosis (MS) is a chronic neuroinflammatory demyelinating disease of the central nervous system (CNS) which is driven by an autoimmune response against CNS-specific myelin proteins that are produced by oligodendrocytes (OL). Various reports have highlighted key factors in the pathogenesis of MS, such as predisposing environmental and genetic causes, as well as inflammation and oxidative stress (i.e. a state of redox imbalance). Oligodendrocytes and their precursors, oligodendrocyte progenitor cells (OPCs), are highly susceptible to oxidative damage, as they possess a high intracellular iron concentration and levels of Polyunsaturated Fatty Acids (PUFA), which are highly susceptible to peroxidation. Furthermore, OL have a high metabolic rate to enable the maintenance of myelin, as well as a lower endogenous free radical scavenging capacity as compared to macrophages and astrocytes. In MS, the pathological immune-mediated attack and associated oxidative stress in oligodendrocytes promotes demyelination, axon degeneration and neuronal dysfunction; this manifests as inflammatory focal lesions within the white matter of the brain, optic nerve, and spinal cord.

[0006] MS can cause significant complications and lower quality of life in patients. Thus, there is a need for new therapeutic interventions for treating multiple sclerosis and for reducing neuroinflammation associated with the disease.

[0007] SUMMARY

[0008] The invention features methods of using the PrC-210 aminothiol to treat or prevent multiple sclerosis (MS) in a subject in need thereof.

[0009] In an aspect, the invention features a method of treating a subject with prodromal multiple sclerosis, said method including administering to the subject an effective amount of a compound of PrC-210,

[0010] HS.

[0011] > HAN HX

[0012] PrC-210

[0013] or a pharmaceutically acceptable salt thereof.

[0014] In some embodiments, the treatment slows the progression of multiple sclerosis in the subject. In some embodiments, the treatment prevents the subject from developing multiple sclerosis.

[0015] In another aspect, the invention features a method of treating a subject with relapsing-remitting multiple sclerosis (RRMS), said method including administering to the subject an effective amount of a compound of PrC-210,

[0016] HS.

[0017] > HAN HX

[0018] PrC-210

[0019] or a pharmaceutically acceptable salt thereof.

[0020] In some embodiments, the subject is experiencing a relapse.PATENT

[0021] ATTORNEY DOCKET NO: 51707-007W02

[0022] In some embodiments, the relapse is reduced in severity or duration.

[0023] In some embodiments, the subject is experiencing remission.

[0024] In some embodiments, the remission is extended in duration.

[0025] In yet another aspect, the invention features a method of treating a subject with primary progressive multiple sclerosis (PPMS), said method including administering to the subject an effective amount of a compound of PrC-210,

[0026] HS.

[0027]

[0028] H H

[0029] PrC-210

[0030] or a pharmaceutically acceptable salt thereof.

[0031] In some embodiments, the subject’s symptoms are reduced in severity or duration.

[0032] In yet another aspect, the invention features a method of treating a subject with secondary progressive multiple sclerosis (SPMS), said method including administering to the subject an effective amount of a compound of PrC-210,

[0033] HS.

[0034]

[0035] H H

[0036] PrC-210

[0037] or a pharmaceutically acceptable salt thereof.

[0038] In some embodiments, the subject is experiencing a relapse.

[0039] In some embodiments, the relapse is reduced in severity or duration.

[0040] In some embodiments, the subject is experiencing remission.

[0041] In some embodiments, the remission is extended in duration.

[0042] In yet another aspect, the invention features a method of treating a subject with progressive relapsing multiple sclerosis (PRMS), said method including administering to the subject an effective amount of a compound of PrC-210,

[0043] HS.

[0044]

[0045] H H

[0046] PrC-210

[0047] or a pharmaceutically acceptable salt thereof.

[0048] In some embodiments, the subject is experiencing a relapse.

[0049] In some embodiments, the relapse is reduced in severity or duration.

[0050] In some embodiments, the subject is experiencing remission.

[0051] In some embodiments, the remission is extended in duration.PATENT

[0052] ATTORNEY DOCKET NO: 51707-007W02

[0053] In yet another aspect, the invention features a method of suppressing demyelination in a subject in need thereof, said method including administering to the subject an effective amount of a compound of PrC-210,

[0054] HS.

[0055]

[0056] H H

[0057] PrC-210

[0058] or a pharmaceutically acceptable salt thereof.

[0059] In some embodiments, the subject has prodromal multiple sclerosis or multiple sclerosis.

[0060] In some embodiments, the suppressing slows the progression of prodromal multiple sclerosis or multiple sclerosis in the subject. In some embodiments, the suppressing prevents the onset of prodromal multiple sclerosis or multiple sclerosis.

[0061] In yet another aspect, the invention features a method of preventing demyelination in a subject in need thereof, said method including administering to the subject an effective amount of a compound of PrC-210,

[0062] HS.

[0063]

[0064] H H

[0065] PrC-210

[0066] or a pharmaceutically acceptable salt thereof.

[0067] In yet another aspect, the invention features a method of reducing the frequency or severity of a flare-up period ora relapse period in a subject suffering from multiple sclerosis, said method including administering to the subject an effective amount of a compound of PrC-210,

[0068] HS.

[0069]

[0070] H H

[0071] PrC-210

[0072] or a pharmaceutically acceptable salt thereof.

[0073] In some embodiments, PrC-210 is administered at the onset of flare-up or relapse symptoms. In some embodiments, the administration of PrC-210 reduces fatigue, weakness, numbness, vision changes, balance problems, bladder issues, or cognitive difficulties in the subject.

[0074] In any of the above aspects or embodiments, PrC-210, or a pharmaceutically acceptable salt thereof, is in a pharmaceutical composition comprising a pharmaceutically acceptable excipient.

[0075] In any of the above aspects or embodiments, PrC-210, or a pharmaceutically acceptable salt thereof, is administered orally, subcutaneously, intravenously, or intraperitoneally.

[0076] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes: (i) during the quiescent period, intravenously administering to the subject an amount of about 0.02 to about 0.40 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, and (ii) during the non-quiescent period, intravenously administering to the subject about 0.15 to about 1.21 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof.PATENT

[0077] ATTORNEY DOCKET NO: 51707-007W02

[0078] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes intravenously administering to the subject an amount of about 0.02 to about 0.40 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, during the quiescent period.

[0079] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes intravenously administering to the subject about 0.15 to about 1.21 mg / kg of PrC-210, ora pharmaceutically acceptable salt thereof, during the non-quiescent period.

[0080] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes: (i) during the quiescent period, orally administering to the subject an amount of about 0.15 to about 6.0 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, and (ii) during the non-quiescent period, orally administering to the subject about 265 to about 4265 mg / kg of PrC-210, ora pharmaceutically acceptable salt thereof.

[0081] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes orally administering to the subject an amount of about 0.15 to about 6.0 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, during the quiescent period.

[0082] In yet another aspect, the invention features a method of reducing flare-up severity in a subject with multiple sclerosis wherein the method includes orally administering to the subject about 265 to about 4265 mg / kg PrC-210, ora pharmaceutically acceptable salt thereof, during the non-quiescent period.

[0083] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes: (i) during the quiescent period, intravenously administering to the subject an amount of about 1 to about 40 mg of PrC-210, or a pharmaceutically acceptable salt thereof, and (ii) during the non-quiescent period, intravenously administering to the subject about 6 to about 125 mg of PrC-210, ora pharmaceutically acceptable salt thereof.

[0084] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes intravenously administering to the subject an amount of about 1 to about 40 mg of PrC-210, or a pharmaceutically acceptable salt thereof, during the quiescent period.

[0085] In yet another aspect, the invention features a method of reducing flare-up severity in a subject with multiple sclerosis wherein the method includes intravenously administering to the subject about 6 to about 125 mg of PrC-210, or a pharmaceutically acceptable salt thereof, during the non-quiescent period.

[0086] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes: (i) during the quiescent period, orally administering to the subject an amount of about 6 to about 780 mg of PrC-210, or a pharmaceutically acceptable salt thereof, and (ii) during the non-quiescent period, orally administering to the subject about 60 to about 3900 mg of PrC-210, or a pharmaceutically acceptable salt thereof.

[0087] In yet another aspect, the invention features a method of treating multiple sclerosis in a subject wherein the method includes orally administering to the subject an amount of about 35 to about 1420 mg of PrC-210, or a pharmaceutically acceptable salt thereof, during the quiescent period.

[0088] In yet another aspect, the invention features a method of reducing flare-up severity in a subject with multiple sclerosis wherein the method includes orally administering to the subject about 265 to about 4265 mg PrC-210, ora pharmaceutically acceptable salt thereof, during the non-quiescent period.PATENT

[0089] ATTORNEY DOCKET NO: 51707-007W02

[0090] In some embodiments, the subject has relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), or progressive relapsing multiple sclerosis (PRMS).

[0091] In some embodiments, the subject is experiences relapses and remissions, and wherein the relapse is reduced in severity or duration; or the remission is extended in duration.

[0092] In yet another aspect, the invention features a method of treating a subject with prodromal multiple sclerosis wherein the method includes administering to the subject an effective amount of a compound of PrC-210, or a pharmaceutically acceptable salt thereof, and wherein:

[0093] a. the method includes intravenously administering to the subject an amount of about 0.02 to about 0.4mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof;

[0094] b. the method includes orally administering to the subject an amount of about 0.71 to about 14.21 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof;

[0095] c. the method includes intravenously administering to the subject an amount of about 1 to about 40 mg of PrC-210, or a pharmaceutically acceptable salt thereof; or

[0096] d. the method includes orally administering to the subject an amount of about 35 to about 1420 mg of PrC-210, or a pharmaceutically acceptable salt thereof.

[0097] In yet another aspect, the invention features a method of suppressing demyelination in a subject in need thereof, wherein the method includes administering to the subject an effective amount of a compound of PrC-210, or a pharmaceutically acceptable salt thereof, and wherein:

[0098] a. the method includes intravenously administering to the subject an amount of about 0.15 to about 1.21 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof;

[0099] b. the method includes orally administering to the subject an amount of about 265 to about 4265 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof;

[0100] c. the method includes intravenously administering to the subject an amount of about 6 to about 125 mg of PrC-210, ora pharmaceutically acceptable salt thereof; or

[0101] d. the method includes orally administering to the subject an amount of about 265 to about 4265 mg of PrC-210, or a pharmaceutically acceptable salt thereof.

[0102] In some embodiments, the administering is from the amount daily to the amount weekly.

[0103] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the prodromal stage, wherein the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about .02 to about 0.40 mg / kg.

[0104] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the advanced stage, wherein the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 0.1 to about 1.21 mg / kg.

[0105] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein the method includes:

[0106] (i) intravenously administering to the subject in the prodromal stage of Multiple Sclerosis the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about .02 to about 0.40 mg / kg; andPATENT

[0107] ATTORNEY DOCKET NO: 51707-007W02

[0108] (ii) after Multiple Sclerosis is in the advanced stage in the subject, intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 0.1 to about 1.21 mg / kg

[0109] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the prodromal stage, wherein the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 1 to about 40 mg.

[0110] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 1 to 10 mg.

[0111] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 5 to 20 mg.

[0112] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 15 to 30 mg.

[0113] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 25 to 40 mg.

[0114] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the advanced stage, wherein the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 5 to about 121 mg.

[0115] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 5 to 20 mg.

[0116] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 10 to 40 mg.

[0117] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 20 to 75 mg.

[0118] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 30 to 100 mg.

[0119] In some embodiments, the method includes intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 40 to 121 mg.

[0120] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein the method includes:

[0121] (i) intravenously administering to the subject in the prodromal stage of Multiple Sclerosis the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 1 to about 40 mg; and

[0122] (ii) after Multiple Sclerosis is in the advanced stage in the subject, intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 5 to about 121 mg.

[0123] In some embodiments, the method includes:

[0124] (i) intravenously administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 1 to 10 mg; andPATENT

[0125] ATTORNEY DOCKET NO: 51707-007W02

[0126] (ii) intravenously administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 10 to 40 mg.

[0127] In some embodiments, the method includes:

[0128] (i) intravenously administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 5 to 20 mg; and

[0129] (ii) intravenously administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 20 to 75 mg.

[0130] In some embodiments, the method includes:

[0131] (i) intravenously administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 15 to 30 mg; and

[0132] (ii) intravenously administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 30 to 100 mg.

[0133] In some embodiments, the method includes:

[0134] (i) intravenously administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 25 to 40 mg; and

[0135] (ii) intravenously administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 40 to 121 mg.

[0136] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the prodromal stage, the method comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 0.71 to about 14.21 mg / kg.

[0137] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the advanced stage, wherein the method includes orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 3.55 to about 42.63 mg / kg.

[0138] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein the method includes:

[0139] (i) orally administering to the subject in the prodromal stage of Multiple Sclerosis the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from about 0.71 to about 14.21 mg / kg; and

[0140] (ii) after Multiple Sclerosis is in the advanced stage in the subject, orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 3.55 to about 42.63 mg / kg.

[0141] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein the progressive neurodegenerative disease is in the prodromal stage, wherein the method includes orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 35 to about 1420 mg.

[0142] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 35 to 175 mg.

[0143] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 175 to 315 mg.PATENT

[0144] ATTORNEY DOCKET NO: 51707-007W02

[0145] In some embodiments, the method includes administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 315 to 500 mg.

[0146] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 200 to 675 mg.

[0147] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 675 to 900 mg.

[0148] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 675 to 1100 mg.

[0149] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 800 to 1420 mg.

[0150] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the advanced stage, wherein the method includes orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 175 to about 4265 mg.

[0151] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 175 to 1200 mg.

[0152] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 315 to 1350 mg.

[0153] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 500 to 1500 mg.

[0154] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 675 to 2000 mg.

[0155] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 900 to 2100 mg.

[0156] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 1100 to 4000 mg.

[0157] In some embodiments, the method includes orally administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 1420 to 4265 mg.

[0158] In yet another aspect, the invention features a method of treating Multiple Sclerosis in a subject in need thereof, the method comprising:

[0159] (i) orally administering to the subject in the prodromal stage of Multiple Sclerosis the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from about 35 to about 1420 mg; and

[0160] (ii) after Multiple Sclerosis is in the advanced stage in the subject, orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 175 to about 4265 mg.

[0161] In some embodiments, the method includes:

[0162] (i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 35 to 175 mg; and

[0163] (ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 175 to 1200 mg.PATENT

[0164] ATTORNEY DOCKET NO: 51707-007W02

[0165] In some embodiments, the method includes:

[0166] (i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 175 to 315 mg; and

[0167] (ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 315 to 1350 mg.

[0168] In some embodiments, the method includes:

[0169] (i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 315 to 500 mg; and

[0170] (ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 500 to 1500 mg.

[0171] In some embodiments, the method includes:

[0172] (i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 200 to 675 mg; and

[0173] (ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 2000 mg.

[0174] In some embodiments, the method includes:

[0175] (i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 900 mg; and

[0176] (ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 900 to 2100 mg.

[0177] In some embodiments, the method includes:

[0178] (i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 1100 mg; and

[0179] (ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 1100 to 4000 mg.

[0180] In some embodiments, the method includes:

[0181] (i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 800 to 1420 mg; and

[0182] (ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 1420 to 4265 mg.

[0183] Definitions

[0184] To facilitate the understanding of this invention, a number of terms are defined below. Terms defined herein have meanings as commonly understood by a person of ordinary skill in the areas relevant to the invention. Terms such as “a”, “an,” and “the” are not intended to refer to only a singular entity, but include the general class of which a specific example may be used for illustration. The terminology herein is used to describe specific embodiments of the invention, but their usage does not limit the invention, except as outlined in the claims.

[0185] As used herein, the term “about” refers to a value that is within 10% above or below the value being described.

[0186] As used herein, any values provided in a range of values include both the upper and lowerPATENT

[0187] ATTORNEY DOCKET NO: 51707-007W02

[0188] bounds, and any values contained within the upper and lower bounds.

[0189] As used herein, the term “pharmaceutically acceptable salt” represents those salts of the compounds described that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and animals without undue toxicity, irritation, allergic response and the like and are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, pharmaceutically acceptable salts are described in: Berge et al., J.

[0190] Pharmaceutical Sciences 66:1-19, 1977 and in Handbook of Pharmaceutical Salts: Properties, Selection, and Use, (Eds. P.H. Stahl and C.G. Wermuth), Wiley-VCH, 2008. These salts may be acid addition salts involving inorganic or organic acids. The salts can be prepared in situ during the final isolation and purification of the compounds described herein or separately by reacting the free base group with a suitable acid.

[0191] As used herein, the term “effective amount” refers to an amount sufficient to effect beneficial or desired results, such as clinical results, and, as such, a “therapeutically effective amount” depends upon the context in which it is being applied. In the context of treating MS, an effective amount of a compound is, for example, an amount sufficient to ameliorate the symptoms or progression of MS. The methods of the invention can include systemic (e.g., intravenous) or local administration (e.g., topical or local injection), as needed depending upon the nature of the condition being treated.

[0192] As used herein, and as well understood in the art, “to treat” a condition or “treatment” of various diseases and disorders is an approach for obtaining beneficial or desired results, such as clinical results. Beneficial or desired results can include, but are not limited to, alleviation of one or more symptoms or conditions; diminishment of extent of disease, disorder, or condition; stabilizing (i.e., not worsening) state of disease, disorder, or condition; delay or slowing the progress of the disease, disorder, or condition; amelioration or palliation of the disease, disorder, or condition; and remission (whether partial or total), whether detectable or undetectable. “Palliating” a disease, disorder, or condition means that the extent and / or undesirable clinical manifestations of the disease, disorder, or condition are lessened and / or time course of the progression is slowed or lengthened, as compared to the extent or time course in the absence of treatment.

[0193] The term “subject,” as used herein, can be a human, non-human primate, or other mammal, such as but not limited to dog, cat, horse, cow, pig, goat, monkey, rat, mouse, and sheep. In preferred embodiments, the subject is a human.

[0194] As used herein, the term “pharmaceutical composition” refers to an active compound, formulated together with one or more pharmaceutically acceptable excipients. In some embodiments, a compound of the invention is present in unit dose amount appropriate for administration in a therapeutic regimen that shows a statistically significant probability of achieving a predetermined therapeutic effect when administered to a relevant population. In certain embodiments, pharmaceutical compositions may be specially formulated for administration in solid or liquid form, including those adapted for the following: oral administration, for example, drenches (aqueous or non-aqueous solutions or suspensions), tablets, or capsules; and parenteral administration, for example, by subcutaneous, intramuscular, or intravenous injection.

[0195] The term “pharmaceutically acceptable excipient,” as used herein, refers to any inactive ingredient (for example, a vehicle capable of suspending or dissolving the active compound) that isPATENT

[0196] ATTORNEY DOCKET NO: 51707-007W02

[0197] biocompatible and suitable for administration to a subject. Typical excipients include, for example: antiadherents, antioxidants, binders, coatings, compression aids, disintegrants, dyes, emollients, emulsifiers, diluents, film formers or coatings, flavors, fragrances, glidants, lubricants, preservatives, printing inks, sorbents, suspending or dispersing agents, sweeteners, or waters of hydration. Excipients include, but are not limited to: butylated optionally substituted hydroxytoluene (e.g., BHT), calcium carbonate, calcium phosphate dibasic, calcium stearate, croscarmellose, crosslinked polyvinyl pyrrolidone, citric acid, crospovidone, cysteine, ethylcellulose, gelatin, optionally substituted hydroxypropyl cellulose, optionally substituted hydroxypropyl methylcellulose, lactose, magnesium stearate, maltitol, mannitol, methionine, methylcellulose, methyl paraben, microcrystalline cellulose, polyethylene glycol, polyvinyl pyrrolidone, povidone, pregelatinized starch, propyl paraben, retinyl palmitate, shellac, silicon dioxide, sodium carboxymethyl cellulose, sodium citrate, sodium starch glycolate, sorbitol, starch, stearic acid, stearic acid, sucrose, talc, titanium dioxide, vitamin A, vitamin E, vitamin C, and xylitol. Those of ordinary skill in the art are familiar with a variety of agents and materials useful as excipients.

[0198] Other features and advantages of the invention will be apparent from the following Detailed Description, the drawings, and the claims.

[0199] Brief Description of the Drawings

[0200] FIG. 1 is a schematic summarizing: 1) the MOG vaccination schedule to initiate EAE pathology in C57 mice; and 2) the PrC-210 dosing protocol for preventing and treating MS in the C57 mouse EAE MS model.

[0201] FIG. 2 is a graph showing EAE clinical scores overtime (post MOG vaccination) in mice treated with MOG alone, MOG and 0.025 MTD PrC-210, MOG and 0.050 MTD PrC-210, MOG and 0.075 MTD PrC-210; or vehicle using the prevention protocol (first trial).

[0202] FIG. 3 is a graph showing EAE clinical scores overtime (post MOG vaccination) in mice treated with MOG alone, MOG and 0.150 MTD PrC-210, MOG and 0.075 MTD PrC-210, or vehicle using the treatment protocol (first trial).

[0203] FIG. 4 is a graph showing E EAE clinical scores overtime (post MOG vaccination) in mice treated with MOG alone, MOG and 0.050 MTD PrC-210; MOG and 0.075 MTD PrC-210, MOG and 0.100 MTD PrC-210, or vehicle using the prevention protocol (second trial).

[0204] FIG. 5 is a graph showing EAE clinical scores overtime (post MOG vaccination) in mice treated with MOG alone, MOG and 0.050 MTD PrC-210, MOG and 0.075 MTD PrC-210, MOG and 0.100 MTD PrC-210, MOG and 0.150 MTD PrC-210, or vehicle using the treatment protocol (second trial).

[0205] FIG. 6 illustrates the degree of spinal column demyelination in EAE Group 1 Vehicle Control (no MOG vaccination), EAE Group 2 (MOG vaccination alone), and EAE Group 8 (MOG vaccination and 0.100 MTD PrC-210 treatment administration). In these samples, spinal columns and ~0.5 cm of tissue flanking the spinal column, from the neck to the tail base, were cut out with scissors from euthanized mice in each indicated group, and fixed in formalin. Following de-calcification, fixed tissues were embedded in paraffin, sectioned in the plane shown in the Figure’s mouse graphical inset, and samples were then stained with LUXOL® Fast Blue to highlight myelin density and uniformity. For each spine image, thePATENT

[0206] ATTORNEY DOCKET NO: 51707-007W02

[0207] lower panel is a 3X enlargement of the spine cross-section above it to better illuminate peripheral spine demyelination in MOG-vaccinated mice, and its substantial suppression by PrC-210.

[0208] FIG. 7 is a table summarizing the substantial efficacy that PrC-210 exhibits in suppressing EAE clinical paralysis scores, whether administered in a Prevention or Treatment regimen to the MOG-vaccinated C57 mice. Scores indicating the relative inefficacy of current MS treatments in the same mouse EAE model system, i.e., edaravone and dimethyl fumarate, are shown for comparison.

[0209] FIG. 8A is a series of white light photographs of gross stomachs from mice after 21 day oral gavage treatment with either: i) 0.08% methylcellulose (vehicle control); ii) 0.08% methylcellulose containing 1.5 mg / ml DMF; or iii) biweekly 0.1 MTD dose (180 mg / kg) of PrC-210. FIG 8B is a series of histology sections (H&E stain) of stomach walls from stomachs shown in panel A (10 X objective).

[0210] FIG. 9 is a series of graphs showing the amount of Caspase 1 inflammatory marker or Caspase 3 / 7 cell death marker in homogenates prepared from stomach walls of stomachs shown in FIG. 8A or in blood plasma from mice that provided the stomachs after 21 day oral gavage treatments.

[0211] FIG. 10 is a series of graphs showing the levels of select blood cell populations in blood recovered from mice after 21 day oral gavage treatment with either methylcellulose control, methylcellulose containing 1.5 mg / ml DMF, or biweekly PrC-210.

[0212] FIG. 11 is a graph showing EAE paralysis suppression overtime in MOG-vaccinated mice treated with vehicle or 15 mg / kg oral gavage dose of DMF (in 0.08% methylcellulose :water).

[0213] FIG. 12 is a schematic summarizing the experimental design to determine PrC-210 pharmacokinetic and toxicokinetic parameters in ~50 kg male and ~50 kg female pigs. Either a single IV bolus injection of PrC-210 was administered via an indwelling venous catheter at 0 min, or a single oral bolus dose of PrC-210 was administered via i) liquid gavage through a gastric feeding tube or ii) precisely weighed gel capsules containing dry PrC-210 HCI crystals followed by a water dose whose volume equaled 1% of the pig’s body weight. Four ml blood aliquots were withdrawn via the catheter at the indicated timepoints. Using a vest-mounted detection device, both blood pressure and ECG were monitored for at least 15 min following the IV bolus injection. Pigs were visually monitored as well to note any changes in behavior associated with the IV PrC-210 injection. Seven days following the PrC-210 dose, every pig was euthanized and underwent necropsy by a veterinary pathologist.

[0214] FIG. 13A and FIG. 13B are graphs showing PrC-210 plasma pharmacokinetics following a single IV bolus injection at the indicated PrC-210 mg / kg doses (IV bolus injection volume = 10 ml / 50 kg bw) in male pigs (FIG. 13A) and in female pigs (FIG. 13B).

[0215] FIG. 14 is a graph showing the plasma PrC-210 AUC plotted against PrC-210 dose.

[0216] Extrapolated, dashed lines show that equivalent IV doses (5.02 mg / kg) administered to both male pigs (circle data markers) and female pigs (square data markers), conferred a roughly 15% higher AUC dose in female pigs.

[0217] FIG. 15A is a graph showing the toxicokinetic response in a male pig administered with an IV PrC-210 dose (29.8 mg / kg) at 0 min via the indwelling venous catheter. All vomit responses through 90 min of direct observation of the pig have been plotted. The 29.8 mg / kg PrC-210 dose was administered before sufficient doses had been administered to other pigs to extrapolate a NOAEL dose of 5.02 mg / kg.

[0218] FIG. 15B is a graph showing the stepwise reduction in IV PrC-210 dose, which was done in multiple male pigs to determine an extrapolated NOAEL dose in male pigs of 5.02 mg / kg.PATENT

[0219] ATTORNEY DOCKET NO: 51707-007W02

[0220] FIG. 16 is a summary of complete blood counts (CBCs) in pigs following IV administration of PrC-210. Pig bloods were drawn at the times indicated into heparinized tubes, and complete blood counts were performed within 24 hours (hr) of drawing (at room temperature) on an Abaxis HM5 Hematology Analyzer. Values shown are the means of three or more pigs at each data point.

[0221] FIG. 17 is a graph showing creatinine levels in pigs before and after IV administration of vehicle or PrC-210.

[0222] FIG. 18 is a series of pig organ histology images (10X images) obtained from organs retrieved from indicated study pigs at necropsy. A control pig received IV saline on Day 0, and the PrC-210 pig received a dose of 29.7 mg / kg PrC-210 (= 5.9 Xthe pig NOAEL dose of 5.02 mg / kg). Blinded necropsy was performed on each pig seven days following the IV PrC-210 dose.

[0223] FIG. 19A is a line graph showing the survival benefit of oral administration of escalating doses of PrC-210 (0.1, 0.2, 0.3, 0.4, 0.5, and 0.6 MTD) 24 hours after 8.25 Gy total body irradiation in ICR mice. Each dose is represented by specific symbols and corresponding alphabetical labels. Survival improves with increasing MTD fractions up to 0.4, beyond which it declines, potentially due to reductive stress.

[0224] FIG. 19B is an overlay of line graphs showing the survival analysis of ICR mice receiving increasing fractions of PrC-210 (0-0.6 MTD) administered orally 24 hours post 8.25 Gy irradiation.

[0225] Symbols and corresponding letters denote each dose group. A dose-dependent survival benefit is observed up to 0.4 MTD, while a decline at 0.6 MTD may reflect excessive free radical scavenging and resultant reductive stress.

[0226] FIG. 20 is a bar graph showing the differences in reductive stress response in 11 Gy irradiated mice treated with and without PrC-210 treatment. Real-time in vivo free radical imaging was performed on mice exposed to 11 Gy irradiation, captured 30 minutes after receiving one of the following treatments: no treatment, 0.5 MTD PrC-210 administered intravenously immediately before imaging, i.e., 30 minutes post-irradiation, or 0.5 MTD PrC-210 administered intravenously 30 minutes prior to irradiation.

[0227] Background levels were assessed in unirradiated mice.

[0228] FIG. 21 is an overlay of four line graphs showing the total body ROS levels in 8.68 Gy irradiated mice. The data markers inculcate the chemiluminescent quantification of ROS levels in 8.6 Gy irradiated mice that were either non-treated, pretreated with PrC-210 at 0.5 MTD, or received PrC-210 at 0.3 MTD after 24 hr post irradiation, that were imaged from 2 hr to 8 days post irradiation. Untreated mice were quantified to establish normal homeostatic ROS levels.

[0229] FIG. 22 is a bar graph showing the chemiluminescent quantification of ROS levels 30 minutes after 8.68 Gy irradiation of mice that received either no treatment, were either given PrC-210 at a dose of 0.5 MTD or 0.1 MTD 30 minutes before irradiation, or that were given a dose of either 0.5 MTD or 0.1 MTD of PrC-21030 minutes after irradiation.

[0230] DETAILED DESCRIPTION

[0231] This invention features the use of the PrC-210 aminothiol for treating or preventing multiple sclerosis (MS) and subsets thereof (e.g., prodromal MS, relapsing-remitting MS, primary progressive MS, secondary progressive MS, and progressive relapsing MS) in a subject in need thereof. The invention also provides methods of suppressing demyelination in a subject in need thereof and methods ofPATENT

[0232] ATTORNEY DOCKET NO: 51707-007W02

[0233] reducing the frequency or severity of a flare-up period or a relapse period in a subject suffering from multiple sclerosis.

[0234] Applicant has discovered that PrC-210 potently reduces neuroinflammation that would otherwise lead to demyelination and the onset of MS. The Examples indicate that PrC-210 suppresses experimental autoimmune encephalomyelitis (EAE) paralysis and demyelination, which would otherwise cause MS.

[0235] PrC-210

[0236] PrC-210 useful in the methods of the invention can be synthesized, e.g., as described in U.S. Patent No. 7,314,959. The two amines of the aminothiol PrC-210 are both positively charged within a very broad physiological pH range, which makes them highly attracted via electrostatic interaction to negative charges on proteins, lipids, sugars, RNA and DNA. DNA, RNA, lipids, sugars, proteins, lipo- and gluco-proteins, all of which have a number of negative charges on their surface. The two positive charges on PrC-210 will be drawn by complementing charges to these negative charges on cell biomolecules. The PrC-210 thiol group shows very low reactivity in water in the absence of negative charges and is highly stable as a monomeric aminothiol. Electrostatic interaction with negative charges in close proximity to the PrC-210 significantly changes the stability of PrC-210 and activates the PrC-210 thiol group.

[0237] In some embodiments, the disclosure features a pharmaceutical composition including PrC-210 and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition including PrC-210 is administered in an amount from about 0.001 mg up to about 500 mg / kg / day (e.g., about 0.1 , about 5.0, about 10, or about 100 mg / kg / day). In some embodiments, the pharmaceutical composition including PrC-210 is administered orally, subcutaneously, intravenously, or intraperitoneally. In some embodiments, the pharmaceutical composition including PrC-210 is administered orally. In some embodiments, the pharmaceutical composition including PrC-210 is administered intravenously.

[0238] Dosing

[0239] The administered dose of the compound of the disclosure depends on factors including the route of administration, the disease to be treated, and physical characteristics, e.g., age, weight, and general health, of the subject. Typically, a pharmaceutical composition of the disclosure can be administered in an amount from about 0.001 mg up to about 500 mg / kg / day of PrC-210 (e.g., about 0.1 , about 1 , about 5.0, about 10, about 20, about 30, about 40, about 50, about 60, about 70, about 80, about 90, or about 100 mg / kg / day).

[0240] The PrC-210 compound used in the methods described herein may be administered initially in a suitable dosage that may be adjusted as required, depending on the clinical response. In general, a suitable daily dose of PrC-210 will be that amount of the compound that is the lowest dose effective to produce a therapeutic effect without adverse events (see, e.g., FIG. 19A and FIG. 19B). Such an effective dose will generally depend upon factors such as age, weight, and condition of the subject. While the attending physician ultimately will decide the appropriate amount and dosage regimen, an effective amount of PrC-210 may be, for example, a total unit dosage of, from about 1 mg to about 10,000 mg of PrC-210.PATENT

[0241] ATTORNEY DOCKET NO: 51707-007W02

[0242] Chronic Progressive Dosing Regimen

[0243] A subject suffering from the prodromal stage of MS may be intravenously administered a dose of PrC-210 from about 0.02 mg / kg to about 0.40 mg / kg (e.g., about 0.02 mg / kg, about 0.04 mg / kg, about 0.06 mg / kg, about 0.08 mg / kg, about 0.10 mg / kg, about 0.12 mg / kg, about 0.15 mg / kg, about 0.18 mg / kg, about 0.2 mg / kg, about 0.22 mg / kg, about 0.25 mg / kg, about 0.28 mg / kg, about 0.3 mg / kg, about 0.32 mg / kg, about 0.35 mg / kg, about 0.38 mg / kg, or about 0.40 mg / kg). A subject suffering from the prodromal stage of MS may be intravenously administered a dose of PrC-210 from about 1 mg to about 40 mg (e.g., about 1 mg, about 2 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, or about 40 mg). A subject suffering from the prodromal stage of MS may be orally administered a dose of PrC-210 from about 0.71 mg / kg to about 14.21 mg / kg (e.g., about 0.71 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 1 mg / kg, about 1 .25 mg / kg, about 1.45 mg / kg, about 1.60 mg / kg, about 1.65 mg / kg, about 1.70 mg / kg, about 1.75 mg / kg, about 2 mg / kg, about 1.25 mg / kg, about 2.5 mg / kg, about 3 mg / kg, about 3.5 mg / kg, about 4 mg / kg, about 4.5 mg / kg, about 5 mg / kg, about 5.5 mg / kg, about 6 mg / kg, about 6.5 mg / kg, about 7 mg / kg, about 8 mg / kg, about 8.5 mg / kg, about 9 mg / kg, about 9.5 mg / kg, about 10 mg / kg, about 10.5 mg / kg, about 11 mg / kg, about 11.5 mg / kg, about 12 mg / kg, about 12.4 mg / kg, about 13 mg / kg, about 13.5 mg / kg, about 14 mg / kg, or about 14.21 mg / kg). A subject suffering from the prodromal stage 3 of MS may be orally administered a dose of PrC-210 from about 35 mg to 1420 mg (e.g., about 35 mg , about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, about 125 mg, about 130 mg, about 135 mg, about 140 mg, about 145 mg, about 150 mg, about 155 mg, about 160 mg, about 165 mg, about 170 mg, about 175 mg, about 180 mg, about 185 mg, about 190 mg, about 195 mg, about 200 mg, about 205 mg, about 210 mg, about 215 mg, about 220 mg, about 225 mg, about 230 mg, about 235 mg, about 240 mg, about 245 mg, about 250 mg, about 255 mg, about 260 mg, about 265 mg, about 270 mg, about 275 mg, about 280 mg, about 285 mg, about 290 mg, about 295 mg, about 300 mg, about 305 mg, about 310 mg, about 315 mg, about 320 mg, about 325 mg, about 330 mg, about 335 mg, about 340 mg, about 345 mg, about 350 mg, about 355 mg, about 360 mg, about 365 mg, about 370 mg, about 375 mg, about 380 mg, about 385 mg, about 390 mg, about 395 mg, about 400 mg, about 405 mg, about 410 mg, about 415 mg, about 420 mg, about 425 mg, about 430 mg, about 435 mg, about 440 mg, about 445 mg, about 450 mg, about 455 mg, about 460 mg, about 465 mg, about 470 mg, about 475 mg, about 480 mg, about 485 mg, about 490 mg, about 495 mg, about 500 mg, about 505 mg, about 510 mg, about 515 mg, about 520 mg, about 525 mg, about 530 mg, about 535 mg, about 540 mg, about 545 mg, about 550 mg, about 555 mg, about 560 mg, about 565 mg, about 570 mg, about 575 mg, about 580 mg, about 585 mg, about 590 mg, about 595 mg, about 600 mg, about 605 mg, about 610 mg, about 615 mg, about 620 mg, about 625 mg, about 630 mg, about 635 mg, about 640 mg, about 645 mg, about 650 mg, about 655 mg, about 660 mg, about 665 mg, about 670 mg, about 675 mg, about 680 mg, about 685 mg, about 690 mg, about 695 mg, about 700 mg, about 705 mg, about 710 mg, about 715 mg, about 720 mg, about 725 mg, about 730 mg, about 735 mg, about 740 mg, about 745 mg, about 750 mg, about 755 mg, about 760 mg, about 765 mg, about 770 mg, about 775 mg, about 780 mg, about 785 mg, about 790 mg, about 795 mg, about 800 mg, about 805 mg, about 810 mg, about 815 mg, about 820 mg, about 825 mg, about 830 mg, about 835 mg, about 840 mg, about 845 mg, about 850 mg, about 855 mg, about 860 mg, about 865 mg, aboutPATENT

[0244] ATTORNEY DOCKET NO: 51707-007W02

[0245] 870 mg, about 875 mg, about 880 mg, about 885 mg, about 890 mg, about 895 mg, about 900 mg, about 905 mg, about 910 mg, about 915 mg, about 920 mg, about 925 mg, about 930 mg, about 935 mg, about 940 mg, about 945 mg, about 950 mg, about 955 mg, about 960 mg, about 965 mg, about 970 mg, about 975 mg, about 980 mg, about 985 mg, about 990 mg, about 995 mg, about 1000 mg, about 1005 mg, about 1010 mg, about 1015 mg, about 1020 mg, about 1025 mg, about 1030 mg, about 1035 mg, about 1040 mg, about 1045 mg, about 1050 mg, about 1055 mg, about 1060 mg, about 1065 mg, about 1070 mg, about 1075 mg, about 1080 mg, about 1085 mg, about 1090 mg, about 1095 mg, about 1100 mg, about 1105 mg, about 1110 mg, about 1115 mg, about 1120 mg, about 1125 mg, about 1130 mg, about 1135 mg, about 1140 mg, about 1145 mg, about 1150 mg, about 1155 mg, about 1160 mg, about 1165 mg, about 1170 mg, about 1175 mg, about 1180 mg, about 1185 mg, about 1190 mg, about 1195 mg, about 1200 mg, about 1205 mg, about 1210 mg, about 1215 mg, about 1220 mg, about 1225 mg, about 1230 mg, about 1235 mg, about 1240 mg, about 1245 mg, about 1250 mg, about 1255 mg, about 1260 mg, about 1265 mg, about 1270 mg, about 1275 mg, about 1280 mg, about 1285 mg, about 1290 mg, about 1295 mg, about 1300 mg, about 1305 mg, about 1310 mg, about 1315 mg, about 1320 mg, about 1325 mg, about 1330 mg, about 1335 mg, about 1340 mg, about 1345 mg, about 1350 mg, about 1355 mg, about 1360 mg, about 1365 mg, about 1370 mg, about 1375 mg, about 1380 mg, about 1385 mg, about 1390 mg, about 1395 mg, about 1400 mg, about 1405 mg, about 1410 mg, about 1415 mg, or about 1420 mg).

[0246] A subject suffering from the advanced stage of MS may be intravenously administered a dose of PrC-210 from about 0.1 mg / kg to about 1.21 mg / kg (e.g., about 0.1 mg / kg, about 0.15 mg / kg, about 0.2 mg / kg, about 0.25 mg / kg, about 0.30 mg / kg, about 0.35 mg / kg, about 0.40 mg / kg, about 0.45 mg / kg, about 0.5 mg / kg, about 0.55 mg / kg, about 0.6 mg / kg, about 0.65 mg / kg, about 0.7 mg / kg, about 0.75 mg / kg, about 0.8 mg / kg, about 0.85 mg / kg, about 0.9 mg / kg, about 0.95 mg / kg, about 1 mg / kg, about 1.10 mg / kg, about 1 .15 mg / kg, or about 1.21 mg / kg). A subject suffering from the advanced stage of MS may be intravenously administered a dose of PrC-210 from about 5 mg to 121 mg (e.g., about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg, about 40 mg, about 45 mg, about 50 mg, about 55 mg, about 60 mg, about 65 mg, about 70 mg, about 75 mg, about 80 mg, about 85 mg, about 90 mg, about 95 mg, about 100 mg, about 105 mg, about 110 mg, about 115 mg, about 120 mg, or about 121 mg). A subject suffering from the advanced stage of MS may be orally administered a dose of PrC-210 from about 3.55 mg / kg to about 42.63 mg / kg (e.g., about 3.55 mg / kg, about 3.75 mg / kg, about 4 mg / kg, about 4.55 mg / kg, about 4.95 mg / kg, about 5.0 mg / kg, about 5.55 mg / kg, about 5.75 mg / kg, about 6 mg / kg, about 6.55 mg / kg, about 7 mg / kg, about 7.75 mg / kg, about 8.0 mg / kg, about 8.55 mg / kg, about 9 mg / kg, about 9.75 mg / kg, about 10 mg / kg, about 10.55 mg / kg, about 11 mg / kg, about 11.75 mg / kg, about 12 mg / kg, about 12.55 mg / kg, about 13 mg / kg, about 13.75 mg / kg, about 14 mg / kg, about 14.55 mg / kg, about 15 mg / kg, about 15.75 mg / kg, about 16 mg / kg, about 16.55 mg / kg, about 17 mg / kg, about 17.75 mg / kg, about 18 mg / kg, about 18.55 mg / kg, about 19 mg / kg, about 19.75 mg / kg, about 20 mg / kg, about 20.55 mg / kg, about 21 mg / kg, about 21.75 mg / kg, about 22 mg / kg, about 22.55 mg / kg, about 23 mg / kg, about 23.55 mg / kg, about 24 mg / kg, about 24.75 mg / kg, about 25 mg / kg, about 25.55 mg / kg, about 26 mg / kg, about 26.75 mg / kg, about 27 mg / kg, about 27.55 mg / kg, about 28 mg / kg, about 28.75 mg / kg, about 29 mg / kg, about 29.55 mg / kg, about 30 mg / kg, about 30.75 mg / kg, about 31 mg / kg, about 31.55 mg / kg, about 32 mg / kg, about 32.75 mg / kg, about 33 mg / kg, aboutPATENT

[0247] ATTORNEY DOCKET NO: 51707-007W02

[0248] 33.55 mg / kg, about 34 mg / kg, about 34.75 mg / kg, about 35 mg / kg, about 35.55 mg / kg, about 36 mg / kg, about 36.75 mg / kg, about 37 mg / kg, about 37.55 mg / kg, about 38 mg / kg, about 38.75 mg / kg, about 39 mg / kg, about 39.55 mg / kg, about 40 mg / kg, about 40.75 mg / kg, about 41 mg / kg, about 41.55 mg / kg, about 42 mg / kg, or about 42.63 mg / kg). A subject suffering from the advanced stage of MS may be orally administered a dose of PrC-210 from about 175 mg to 4265 mg (e.g., about 175 mg, about 200 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, about 500 mg, about 510 mg, about 520 mg, about 530 mg, about 540 mg, about 550 mg, about 560 mg, about 570 mg, about 580 mg, about 590 mg, about 600 mg, about 610 mg, about 620 mg, about 630 mg, about 640 mg, about 650 mg, about 660 mg, about 670 mg, about 700 mg, about 750 mg, about 800 mg, about 850 mg, about 900 mg, about 950 mg, about 1000 mg, about 1050 mg, about 1100 mg, about 1150 mg, about 1200 mg, about 1250 mg, about 1300 mg, about 1350 mg, about 1400 mg, about 1450 mg, about 1500 mg, about 1550 mg, about 1600 mg, about 1650 mg, about 1700 mg, about 1750 mg, about 1800 mg, about 1850 mg, about 1900 mg, about 1950 mg, about 2000 mg, about 2050 mg, about 2100 mg, about 2150 mg, about 2200 mg, about 2250 mg, about 2300 mg, about 2350 mg, about 2400 mg, about 2450 mg, about 2500 mg, about 2550 mg, about 2600 mg, about 2650 mg, about 2700 mg, about 2750 mg, about 2800 mg, about 2850 mg, about 2900 mg, about 2950 mg, about 3000 mg, about 3050 mg, about 3100 mg, about 3150 mg, about 3200 mg, about 3250 mg, about 3300 mg, about 3350 mg, about 3400 mg, about 3450 mg, about 3500 mg, about 3550 mg, about 3600 mg, about 3650 mg, about 3700 mg, about 3750 mg, about 3800 mg, about 3850 mg, about 3900 mg, about 3950 mg, about 4000 mg, about 4050 mg, about 4100 mg, about 4150 mg, about 4200 mg, or about 4265 mg).

[0249] In some embodiments, PrC-210 is only administered to a subject having the advanced stage of MS.

[0250] Administration of PrC-210 may be in a single dose or in multiple doses. When multiple doses are administered, the doses may be separated from one another by, for example, 1-24 hours, 1-7 days, 1-4 weeks, or 1-12 months. PrC-210 be administered according to a schedule, for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , or 12 times per day, every 2nd, 3rd, 4th, 5th, or 6th day, 1 , 2, 3, 4, 5, 6, or 7 times per week, 1 , 2, 3, 4, 5, or 6 times per month, or 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , or 12 times per year. It is to be understood that, for any particular subject, specific dosage regimes should be adjusted overtime according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

[0251] While the attending physician ultimately will decide the appropriate amount and dosage regimen, an effective amount of a compound of the invention may be, for example, a total unit dosage of, e.g., between about 1 mg to about 10,000 mg of PrC-210.

[0252] In some embodiments, the PrC-210 is administered as part of an oral dosage form including between 35 mg to 4500 mg of PrC-210. In some embodiments, the PrC-210 is administered as part of an oral dosage form including from 35 mg to 250 mg. In some embodiments, the PrC-210 is administered as part of an oral dosage form including from 225 mg to 450 mg. In some embodiments, the PrC-210 is administered as part of an oral dosage form including between 575 mg to 1150 mg. In somePATENT

[0253] ATTORNEY DOCKET NO: 51707-007W02

[0254] embodiments, the PrC-210 is administered as part of an oral dosage form including between 680 mg to 1360 mg. In some embodiments, the PrC-210 oral dosage form is administered as a bolus dose.

[0255] In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 1 mg to 350 mg. In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 1 mg to 75 mg. In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 90 mg to 275 mg. In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 50 mg to 115 mg. In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 135 mg to 290 mg. In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 160 mg to 340 mg. In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is 2 mg, 5 mg, 15 mg, 25 mg, 35 mg, 40 mg, 50 mg, 75 mg, 90 mg, 125 mg, 150 mg, 180 mg, 230 mg, 250 mg, or 270 mg.

[0256] Alternatively, the dosage amount can be calculated using the body weight of the patient. Such dose ranges may include, for example, PrC-210 in an amount from about 0.001 mg / kg / day up to about 500 mg / kg / day (e.g., about 0.02, about 0.1 , about 0.7, about 3.0, about 5.0, about 10, about 15, about 30, about 40, about 50, about 75, or about 100 mg / kg / day). In some embodiments, 1.2, 1.3, 1.4, 1.5, 1.5, 1.7, 1.8, 1.9, 2.0, 2.1, 2.2, 2.3, 2.4, or 2.5 mg / kg / day of PrC-210, ora pharmaceutically acceptable salt thereof is administered. In some embodiments, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, or 35 mg / kg / day of PrC-210, ora pharmaceutically acceptable salt thereof is administered to the subject.

[0257] Intermittent Dosing

[0258] The dose administered correlates to the quiescent period and a non-quiescent period of the condition. Higher doses of PrC-210 are effective when the subject is experiencing high oxidative stress, such as during the non-quiescent period. However, these high doses of PrC-210 may lead to adverse reductive stress if administered during the quiescent period. Thus, the dose is adjusted to be lower during the quiescent period. In some specific embodiments, a subject with the quiescent period of the condition is orally administered from 0.71 to 14.21 mg / kg of PrC-210. In some specific embodiments, a subject with the non-quiescent period of the condition is orally administered from 5.33 to 42.63 mg / kg of PrC-210. In some specific embodiments, a subject with the quiescent period of the condition is intravenously administered from 0.02 to 0.4 mg / kg of PrC-210. In some specific embodiments, a subject with the non-quiescent period of the condition is intravenously administered from 0.15 to 1.21 mg / kg of PrC-210.

[0259] In some embodiments, the PrC-210 is administered as part of an oral dosage form including from 30 mg to 4500 mg of PrC-210 (e.g., from 30 mg to 1450 mg, from 35 mg to 1420 mg, from 150 mg to 1500 mg, from 1000 mg to 3000 mg, from 2000 mg to 4000 mg, from 2500 mg to 4500 mg, from 200 mg to 4000 mg, or from 265 mg to 4265 mg). In some embodiments, the PrC-210 is administered as part of an oral dosage form including from 30 mg to 1420 mg (e.g., from 30 mg to 230 mg, from 35 mg to 1420 mg, from 35 mg to 500 mg, from 120 mg to 1120 mg, or from 1000 mg to 1420 mg). In some embodiments, the PrC-210 is administered as part of an oral dosage form including from 225 mg to 450 mg (e.g., from 225 mg to 275 mg, from 250 mg to 300, from 275 mg to 325 mg, from 300 mg to 350 mg, from 325 mg to 425 mg, from 350 mg to 400 mg, or from 400 mg to 450 mg). In some embodiments, the PrC-210 is administered as part of an oral dosage form including from 575 mg to 1150 mg (e.g., from 575PATENT

[0260] ATTORNEY DOCKET NO: 51707-007W02

[0261] mg to 775 mg, from 600 mg to 800 mg, from 775 mg to 975 mg, from 800 mg to 1000 mg, from 975 mg to 1150 mg, or from 1000 mg to 1150 mg). In some embodiments, the PrC-210 is administered as part of an oral dosage form including from 680 mg to 1360 mg (e.g., from 680 mg to 980 mg, from 750 mg to 1050 mg, from 960 mg to 1160 mg, from 1000 mg and 1200 mg, from 1160 mg to 1360 mg, or from 1200 mg to 1360 mg). In some embodiments, PrC-210 is in an oral dosage form containing 35±5 mg, 45±5 mg, 50±5 mg, 55±5 mg, 65±5 mg, 75±5 mg, 85±5 mg, 95±5 mg, 100±5 mg, 105±5 mg, 115±5 mg, 125±5 mg, 135±5 mg, 145±5 mg, 150±5 mg, 155±5 mg, 165±5 mg, 175±5 mg, 185±5 mg, 195±5 mg, 200±5 mg, 205±5 mg, 215±5 mg, 225±5 mg, 235±5 mg, 245±5 mg, 250±5 mg, 255±5 mg, 265±5 mg, 275±5 mg, 285±5 mg, 295±5 mg, 300±5 mg, 305±5 mg, 315±5 mg, 325±5 mg, 335±5 mg, 345±5 mg, 350±5 mg, 355±5 mg, 365±5 mg, 375±5 mg, 385±5 mg, 395±5 mg, 400±5 mg, 405±5 mg, 415±5 mg, 425±5 mg, 435±5 mg, 445±5 mg, 450±5 mg, 455±5 mg, 465±5 mg, 475±5 mg, 485±5 mg, 495±5 mg, 500±5 mg, 505±5 mg, 515±5 mg, 525±5 mg, 535±5 mg, 545±5 mg, 550±5 mg, 555±5 mg, 565±5 mg, 575±5 mg, 585±5 mg, 595±5 mg, 600±5 mg, 605±5 mg, 610±5 mg, 615±5 mg, 625±5 mg, 635±5 mg, 645±5 mg, 650±5 mg, 655±5 mg, 665±5 mg, 675±5 mg, 685±5 mg, 695±5 mg, 700±5 mg, 705±5 mg, 715±5 mg, 725±5 mg, 735±5 mg, 745±5 mg, 750±5 mg, 755±5 mg, 765±5 mg, 775±5 mg, 785±5 mg, 795±5 mg, 800±5 mg, 805±5 mg, 810±5 mg, 815±5 mg, 825±5 mg, 835±5 mg, 845±5 mg, 850±5 mg, 855±5 mg, 865±5 mg, 875±5 mg, 885±5 mg, 895±5 mg, 900±5 mg, 905±5 mg, 910±5 mg, 915±5 mg, 925±5 mg, 935±5 mg, 945±5 mg, 950±5 mg, 955±5 mg, 965±5 mg, 975±5 mg, 985±5 mg, 995±5 mg, 1000±5 mg, 1005±5 mg, 1015±5 mg, 1025±5 mg, 1035±5 mg, 1045±5 mg, 1050±5 mg, 1055±5 mg, 1065±5 mg, 1075±5 mg, 1085±5 mg, 1095±5 mg, 1100±5 mg, 1105±5 mg, 1115±5 mg, 1125±5 mg, 1135±5 mg, 1145±5 mg, 1150±5 mg, 1155±5 mg, 1165±5 mg, 1175±5 mg, 1185±5 mg, 1195±5 mg, 1200±5 mg, 1205±5 mg, 1215±5 mg, 1225±5 mg, 1235±5 mg, 1245±5 mg, 1250±5 mg, 1255±5 mg, 1265±5 mg, 1275±5 mg, 1285±5 mg, 1295±5 mg, 1300±5 mg, 1305±5 mg, 1315±5 mg, 1325±5 mg, 1335±5 mg, 1345±5 mg, 1350±5 mg, 1355±5 mg, 1365±5 mg, 1375±5 mg, 1385±5 mg, 1395±5 mg, 1400±5 mg, 1405±5 mg, 1415±5 mg, 1425±5 mg, 1435±5 mg, 1445±5 mg, 1450±5 mg, 1455±5 mg, 1465±5 mg, 1475±5 mg, 1485±5 mg, 1495±5 mg, or 1500±5 mg of PrC-210. In some embodiments, PrC-210 is in an oral dosage form containing 1400±50 mg, 1450±50 mg, 1500±50 mg, 1550±50 mg, 1600±50 mg, 1650±50 mg, 1700±50 mg, 1750±50 mg, 1800±50 mg, 1850±50 mg, 1900±50 mg, 1950±50 mg, 2000±50 mg, 2050±50 mg, 2100±50 mg, 2150±50 mg, 2200±50 mg, 2250±50 mg, 2300±50 mg, 2350±50 mg, 2400±50 mg, 2450±50 mg, 2500±50 mg, 2550±50 mg, 2600±50 mg, 2650±50 mg, 2700±50 mg, 2750±50 mg, 2800±50 mg, 2850±50 mg, 2900±50 mg, 2950±50 mg, 3000±50 mg, 3050±50 mg, 3100±50 mg, 3150±50 mg, 3200±50 mg, 3250±50 mg, 3300±50 mg, 3350±50 mg, 3400±50 mg, 3450±50 mg, 3500±50 mg, 3550±50 mg, 3600±50 mg, 3650±50 mg, 3700±50 mg, 3750±50 mg, 3800±50 mg, 3850±50 mg, 3900±50 mg, 3950±50 mg, 4000±50 mg, 4050±50 mg, 4100±50 mg, 4150±50 mg, 4200±50 mg, or 4250±50 mg. In some embodiments, the PrC-210 oral dosage form is administered as a bolus dose.

[0262] In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 1 mg to 350 mg (e.g., from 1 mg to 40 mg, from 5 mg to 50 mg, from 6 mg to 125 mg, from 50 mg to 100 mg, from 100 mg to 150 mg, from 150 mg to 200 mg, from 200 mg to 250 mg, from 250 mg to 300 mg, from 300 mg to 350 mg). In some embodiments, PrC-210 is administered intravenously from 1 mg and 40 mg (e.g., from 1 mg to 10 mg, from 10 mg to 20 mg, from 20 mg to 30 mg, or from 30 mg to 40 mg). In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is fromPATENT

[0263] ATTORNEY DOCKET NO: 51707-007W02

[0264] 90 mg to 125 mg (e.g., from 90 mg to 100 mg, from 100 mg to 115 mg, orfrom 110 mg to 125 mg). In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 50 mg to 115 mg (e.g., from 50 mg to 75 mg, from 75 mg to 100 mg, or from 100 mg to 115 mg). In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is from 135 mg to 290 mg (e.g., from 135 mg to 175 mg, from 150 mg to 250 mg, from 175 mg to 275 mg, from 190 mg to 290 mg, or from 240 mg to 290 mg). In some embodiments, the PrC-210 is administered intravenously from 6 mg to 125 mg (e.g., from 6 mg to 12 mg, from 10 mg to 50 mg, from 25 mg to 75 mg, from 50 mg to 100 mg, from 25 mg to 125 mg, orfrom 75 mg to 125 mg). In some embodiments, the PrC-210 is administered intravenously wherein the PrC-210 dose is 1±3 mg, 6±3 mg, 10±3 mg, 12±3 mg, 15±3 mg, 25±3 mg, 35±3 mg, 40±3 mg, 50±3 mg, 75±3 mg, 90±3 mg, 100±3 mg, 115±3 mg, or 125±3 mg Alternatively, the dosage amount can be calculated using the body weight of the patient. Such dose ranges may include, for example, PrC-210 in an amount from about 0.001 mg / kg / day up to about 500 mg / kg / day (e.g., about 0.02, about 0.15, about 0.4, about 0.7, about 1.21 , about 2.5, about 5.0, about 10, about 14.21 , about 25, about 42.63, or about 100 mg / kg / day). In some embodiments, 0.7±0.2, 0.8±0.2, 0.9±0.2, 1.0±0.2, 1.1 ±0.2, 1.2±0.2, 1.3±0.2, 1.4±0.2, 1.5±0.2, 1.6±0.2, 1.7±0.2, 1.8±0.2, 1.9±0.2, 2.0±0.2, 2.1 ±0.2, 2.2±0.2, 2.3±0.2, 2.4±0.2, 2.5±0.2, 3±0.2, 4±0.2, or 5±0.2 mg / kg / day of PrC-210, or a pharmaceutically acceptable salt thereof is administered. In some embodiments, 3±1 , 4±1 , 5±1 , 6±1 , 7±1 , 8±1 , 9±1 , 10±1 , 11±1 , 12±1 , 13±1 , 14±1 , 15±1 , 16±1 , 17±1 , 18±1 , 19±1 , 20±1 , 21±1 , 22±1 , 23±1 , 24±1 , 25±1 , 26±1 , 27±1 , 28±1 , 29±1 , 30±1 , 31 ±1 , 32±1 , 33±1 , 34±1 , 35±1 , 36±1 , 37±1 , 38±1 , 39±1 , 40±1 , 41 ±1 , 42±1 , 43±1 , 44±1 , or 45±1 mg / kg / day of PrC-210, or a pharmaceutically acceptable salt thereof is administered to the subject.

[0265] In the methods of the invention, the time period during which multiple doses of a compound of the invention are administered to a patient can vary. For example, in some embodiments, doses of the compounds of the invention are administered to a patient over a time period that is 1-7 days; 1-12 weeks; or 1-3 months. In some embodiments, the compounds are administered to the patient over a time period that is, for example, 4-11 months or 1-30 years. In some embodiments, dose or doses are administered to a patient at the onset of symptoms. In any of these embodiments, the amount of compound that is administered may vary during the time period of administration. When a dose is administered daily, administration may occur, for example, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , or 12 times per day. In some embodiments, a dose is administered only one time (e.g., a bolus dose).

[0266] Dosing Frequency

[0267] Administration of PrC-210 may be in a single dose or in multiple doses. When multiple doses are administered, the doses may be separated from one another by, for example, 1-24 hours, 1-7 days, 1-4 weeks, or 1-12 months. PrC-210 be administered according to a schedule, for example, 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , or 12 times per day, every 2nd, 3rd, 4th, 5th, or 6th day, 1 , 2, 3, 4, 5, 6, or 7 times per week, 1 , 2, 3, 4, 5, or 6 times per month, or 1 , 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 , or 12 times per year. It is to be understood that, for any particular subject, specific dosage regimes should be adjusted overtime according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.PATENT

[0268] ATTORNEY DOCKET NO: 51707-007W02

[0269] Methods of Treatment or Prevention

[0270] The invention involves administration of the PrC-210 aminothiol to treat or prevent multiple sclerosis in a subject. The invention also features methods of administering PrC-210 to suppress demyelination in a subject. As shown in the Examples, Applicant discovered that i) PrC-210 exhibited potent suppression of MS severity (up to 62% suppression of paralysis scores versus vehicle controls, P=0.0001), whether PrC-210 was administered in a “prevention” regimen or a “treatment” regimen, i.e., treatment started at the onset of discernible MS paralysis; ii) the best PrC-210 suppression of paralysis was seen in the same PrC-210 treatment group that showed the best histological evidence of PrC-210-induced integrity of spinal structure and suppressed spinal demyelination; and iii) significant dimethyl fumarate (DMF) toxicity was observed in both mouse gastric and blood cell compartments at a daily DMF dose (15 mg / kg) that showed no detectable suppression of EAE paralysis. The Applicant’s results indicate that systemic PrC-210, which provides widespread, direct scavenging of all activated oxygen and nitrogen free radical species, is suitable for treating MS.

[0271] Multiple sclerosis

[0272] The methods of the invention can be used to treat multiple sclerosis (MS). MS is a chronic, inflammatory, and neurodegenerative disease of the central nervous system characterized by myelin sheath damage in nerve fibers of the brain and spinal cord. The prodromal stage of MS may be characterized by the period before the first demyelinating event (the defining characteristic of MS) when subtle, nonspecific symptoms may appear. Individuals in the prodromal phase may experience increased healthcare visits due to symptoms like fatigue, pain, psychiatric disorders (anxiety, depression), and cognitive issues. The prodromal phase can extend for several years (5-10 years) before the first MS event. MS may be in different forms. For example, Primary Progressive MS (PPMS) is a form of MS where symptoms steadily worsen overtime without periods of remission or flare-ups. Another type, Secondary Progressive MS (SPMS), can evolve from Relapsing-Remitting MS (RRMS) and also involve a progression of symptoms without distinct relapses.

[0273] Prodromal Multiple Sclerosis

[0274] The methods of the invention can be used to treat or prevent prodromal multiple sclerosis in a subject. Prodromal multiple sclerosis refers to early-stage MS, wherein the subject experiences symptoms that may not be recognized as MS. The prodromal phase of MS can last several years, usually occurring 5-10 years before a formal MS diagnosis. Symptoms during the prodromal phase are nonspecific and may include fatigue, headache, pain, urinary problems, and even psychiatric symptoms.

[0275] Relapsing-Remitting Multiple Sclerosis (RRMS)

[0276] The methods of the invention can be used to treat or prevent RRMS in a subject. RRMS is the most common type of MS, characterized by periods of relapses (i.e., worsening symptoms) followed by periods of remission (i.e., improved symptoms).PATENT

[0277] ATTORNEY DOCKET NO: 51707-007W02

[0278] Primary Progressive Multiple Sclerosis (PPMS)

[0279] The methods of the invention can be used to treat or prevent PPMS in a subject. PPMS is characterized by continuous worsening of symptoms from the onset of MS, without any distinct periods of relapses or remission.

[0280] Secondary Progressive Multiple Sclerosis (SPMS)

[0281] The methods of the invention can be used to treat or prevent SPMS in a subject. SPMS is characterized by continuous worsening of symptoms from the onset of MS after an initial period of RRMS.

[0282] Progressive Relapsing Multiple Sclerosis (PRMS)

[0283] The methods of the invention can be used to treat or prevent PRMS in a subject. PRMS is characterized by steady worsening symptoms from the onset of MS, with occasional relapses and remissions.

[0284] Demyelination and Neuroinflammation

[0285] The methods of the invention can be used to suppress or prevent demyelination in a subject. Also provided are methods of reducing or preventing demyelinating diseases (e.g., MS, Neuromyelitis optica, idiopathic inflammatory demyelinating diseases, central pontine myelinolysis, Guillain-Barre syndrome, and anti-MAG peripheral neuropathy). Demyelination occurs when the myelin sheath of nerve fibers is damaged or destroyed. The damage to the myelin sheath can disrupt nerve signals, leading to neuroinflammation and neurodegeneration.

[0286] Flare-ups and Relapses Associated with MS

[0287] The methods of the invention can be used to reduce the frequency or severity of a flare-up period or a relapse period in a subject suffering from multiple sclerosis. A flare-up or relapse associated with MS is a period when new or worsening MS symptoms occur. Symptoms commonly associated with MS flare-ups and relapses include fatigue, weakness, numbness, vision changes, balance problems, bladder issues, and / or cognitive difficulties.

[0288] The following examples are meant to illustrate the invention. They are not meant to limit the invention in any way.

[0289] EXAMPLES

[0290] The disclosure is further illustrated by the following examples, which are not to be construed as limiting this disclosure in scope or spirit to the specific procedures herein described. It is to be understood that the examples are provided to illustrate certain embodiments and that no limitation to the scope of the disclosure is intended thereby. It is to be further understood that resort may be had to various other embodiments, modifications, and equivalents thereof which may suggest themselves to those skilled in the art without departing from the spirit of the present disclosure or scope of the appended claims.PATENT

[0291] ATTORNEY DOCKET NO: 51707-007W02

[0292] Example 1: Prevention of EAE paralysis in the murine EAE model using PrC-210 (trial 1, lower dose)

[0293] This study examined the effect of PrC-210 in preventing EAE paralysis in the murine EAE model. To induce EAE, on Day 0, mice received 2 X 100 pl SC (subcutaneous) injections of the prepared Hooke emulsion containing both MOG35-55 peptide (~285 ug total administered) plus Freund’s Adjuvant on their dorsal back, and single IP (intraperitoneal) injections of Pertussis Toxin (110 ng / injection) on Day 0 and Day +2.

[0294] As shown in the FIG.1, in the “Prevention Protocol,” mice received IP injections of the indicated doses of PrC-210 twice per week, starting on Day -1, a day before the MOG vaccination). The PrC-210 IP MTD (Maximum Tolerated Dose) is 524 mg / kg bw. Each mouse was scored daily for its EAE clinical score using the widely accepted criteria.

[0295] Vaccination of C57BL / 6 mice with MOG peptide followed by Freund’s Adjuvant and Pertussis Toxin resulted in the onset of progressive paralysis on or around Days 10-12, with initial tail tip paralysis, which then progressed into rear limbs and eventually into front limbs. Mice were euthanized when paralysis was sufficiently debilitating to preclude ready access to food pellets and / or gelatinized water placed on the cage bedding.

[0296] In this first test to determine whether systemic PrC-210 administration would suppress the severity of the EAE paralysis, first intraperitoneal (IP) injections of PrC-210 at three different doses, 0.025, 0.050, or 0.075 fractions of the PrC-210 IP Maximum Tolerated Dose (MTD; the mouse MTD for IP PrC-210 injection is 504 mg / kg body weight; the MTD essentially equals a dose lethal to 1% of the injected mice) were administered one day before the MOG vaccination (FIG. 1). These doses were then continued twice per week until euthanasia. Whether compared at “peak” paralysis scores (FIG. 2) or at “end” paralysis scores, mice treated with 0.075 MTD PrC-210 showed a profound 60% suppression of paralysis (P = 0.003, 0.004). Because of the large standard deviations in the group scores, which are common in the EAE system, PrC-210 doses of 0.025 or 0.050 did not produce a statistically significant score reduction.

[0297] Example 2: Treatment regimen to suppress EAE paralysis in the murine EAE model using PrC-210 (trial 1 , lower dose)

[0298] This study examined the effect of PrC-210 in treating EAE paralysis in the murine EAE model. Because risk-factors for MS disease development, and its time of onset in human populations are not clearly defined, the effect of systemic PrC-210 administration was evaluated in a biweekly “treatment” regimen in which the first PrC-210 IP injection began on Day 10 after one or more of the vaccinated mice demonstrated tail tip paralysis (FIG. 3). When comparing end paralysis scores, mice that received 0.075 MTD PrC-210 from Day 10 forward showed a sizable 45% suppression of paralysis (P = 0.010) when compared to vehicle controls. Mice that received twice that dose level, 0.150 MTD, showed a lesser response.PATENT

[0299] ATTORNEY DOCKET NO: 51707-007W02

[0300] Example 3: Prevention of EAE paralysis in the murine EAE model using a higher dose of PrC-210 (trial 2)

[0301] As was done in Example 1 , C57 mice received IP drug twice weekly starting one day before the MOG vaccination (FIG. 1). Because the highest dose tested in the first prevention experiment (0.075 MTD) yielded the best protection, a higher PrC-210 dose (0.100 MTD) was added to see if it would work the same or better (FIG. 4). The 0.075 MTD group protection efficacy (P = 0.008) was similar to that seen in the initial prevention protocol done months earlier (FIG. 2). The 0.100 MTD PrC-210 group here yielded a substantial 60% suppression (P = 0.0001) of paralysis (FIG. 4).

[0302] Example 4: Treatment regimen to suppress EAE paralysis in the murine EAE model using a higher dose of PrC-210 (trial 2)

[0303] In this larger treatment study, groups of C57 mice were injected starting on Day 12 after MOG vaccination with either 0.050, 0.075, 0.100 or 0.150 MTD PrC-210, twice weekly. PrC-210 treatment of these mice as they actively develop substantial EAE-induced paralysis has a substantial effect in suppressing the severity of that process (FIG. 5). All of the PrC-210 dose groups showed a significantly suppressed severity of the developed paralysis. The 62% paralysis suppression seen in the 0.100 MTD dose group (P = 0.0001) was the largest effect seen, but all of the PrC-210 groups showed substantial efficacy, even when they were first administered starting on Day 12 post-MOG vaccination.

[0304] Example 5: Spinal histology of murine EAE model treated with PrC-210

[0305] This Example examined the effect of PrC-210 on the spinal histology of EAE mice. On Day 20 post-MOG vaccination, 2-3 mice from both Vehicle control and each PrC-210 treatment group were euthanized and their spinal column was removed en bloc, formalin fixed, de-calcified, sectioned, and stained with hematoxylin-eosin (H&E) or Luxol Fast Blue to preferentially highlight myelin integrity in the spine cross sections (FIG. 6). The myelin integrity in the EAE-Grp 1 vehicle controls (no MOG vaccination) is apparent, both in the low power complete spine cross section, as well as the 3X magnification of spinal column periphery.

[0306] Spine cross sections from two mice in EAE-Group 2 which received MOG vaccination without treatment show readily apparent demyelination and structural destruction of the spinal column periphery, completely consistent with the widespread rear and front limb paralysis seen in these Group 2 mice.

[0307] Spine cross sections from two Grp 8 mice (0.100 MTD) showed intact spinal integrity with little or no evidence of demyelination. This correlates extremely well with the 62% suppression of EAE paralysis scores seen in Group 8 (FIG. 5), mice which had received biweekly injections of 0.100 MTD PrC-210.

[0308] Example 6: Stomach tissue toxicity of PrC-210 in murine EAE model after oral administration Gastrointestinal toxicities have been commonly reported in humans who receive long term administration of dimethyl fumarate (DMF). Following 21 days of daily, oral gavage treatment with 15 mg / kg DMF, a regimen commonly used in the mouse EAE model, mice were euthanized and the rinsedPATENT

[0309] ATTORNEY DOCKET NO: 51707-007W02

[0310] stomach tissue was examined by both gross, white-light photography of the stomach tissue and by fixation and then H&E staining and microscopic analysis of the gastric wall.

[0311] Each white-light stomach wall image was gathered into a single field image, and the collection of images were then equally “lightened” by +20%. FIG. 8A shows that there was significant erythema throughout the DMF-exposed mouse stomachs. There was no detectable erythema in either the methyl cellulose controls or in the mice given the twice-weekly, 0.1 MTD PrC-210 treatment that conferred maximum suppression of EAE clinical scores in FIGs. 2-7. Analysis of histology sections of the gastric walls (FIG. 8B) reinforced the white-light image analysis. There was significant erosion of the gastric mucosa in DMF-treated mice; this was accompanied by significant infiltration of the mucosa by basophilic inflammatory cells. This histologic basophilia, not seen in control or PrC-210-treated mice, explains the deeper red-blue coloration of DMF-treated stomachs under white light (FIG. 8A).

[0312] Both stomach wall homogenates and plasma from each treatment group mouse were analyzed in vitro to determine whether elevated levels of either or both inflammatory and cell death biomarkers were found to be associated with the stomach wall erythema seen in the DMF-treated mice. The caspase 1 “inflammasome” level in DMF-treated stomachs was significantly elevated (P=0.032) with a slight increase in plasma caspase 1 activity (FIG. 9). Interestingly, the caspase 3 / 7 cell death marker was also significantly elevated in the DMF-treated stomachs (P=0.032) with no detectable elevation in plasma caspase 3 / 7 level.

[0313] Literature studies have reported “leukopenia” in mice treated with DMF, so we performed complete blood counts on whole blood recovered from each mouse in this toxicity study. In FIG. 10, the 21 -day DMF treatment was associated with a significant decrease in neutrophils (P=0.04) and a profound decrease in monocytes (P=0.001). There was no effect on CBC endpoints in PrC-210-treated mice.

[0314] Caspase 1 Assay Method

[0315] Activated caspase 1 activity in mouse stomach homogenate or 20 pl of mouse plasma was determined using the Caspase-Gio 1 Inflammasome Assay (#G9951 , Promega, Madison, Wl). The activated caspase 1 assay was performed as follows: Twenty pl of mouse plasma (stored at -80°C) or stomach homogenate was mixed with 30 pl buffer and 50 pL of the Z-WEHD caspase 1 substrate in the well of a white, opaque, 96 well plate. The plate was shaken at 200 rpm for 60 sec and then allowed to sit at room temperature for 30 min. Chemiluminescence in the wells was measured using a BMG Clariostar luminescence plate reader. A caspase 1 internal standard was included in each experiment.

[0316] Caspase 3 / 7 Assay Method

[0317] Activated caspase 3 / 7 activity in mouse stomach homogenate or 20 pl of mouse plasma was determined using the Apo-ONE Caspase 3 / 7 Assay (#G7790, Promega, Madison, Wl). The activated caspase assay was performed as follows: Twenty pl of mouse plasma (stored at -80°C) or stomach homogenate was mixed with 30 pl buffer and 50 pL of the undiluted Apo-ONE substrate in the well of a black, opaque, 96 well plate to initiate the 60 min reaction. Foil-covered plates were shaken at 200 RPM at 37°C for 60 min. The DEVD caspase substrate peptide cleavage was measured using a BMG Clariostar fluorescent plate reader at an excitation wavelength of 499 nm and an emission wavelength ofPATENT

[0318] ATTORNEY DOCKET NO: 51707-007W02

[0319] 521 nm. A caspase 3 / 7 internal standard was included in each experiment to enable comparison between days.

[0320] Mouse Blood Complete Blood Count (CBC) Method

[0321] Mouse blood that had been collected in EDTA-containing tubes was maintained at room temperature prior to the CBC determination done using an Abaxis HM5 Hematology Analyzer.

[0322] Example 6: Oral dimethyl fumarate efficacy in suppressing EAE paralysis

[0323] A 15 mg / kg oral gavage dose of DMF (in 0.08% methylcellulose:water) was administered daily to MOG-vaccinated mice starting the day of MOG vaccination and continued for 21 days. Control mice received the methylcellulose vehicle only. There was an N of 12 mice in each treatment group. Twenty-one-day oral gavage treatment with 15 mg / kg / day DMF of MOG-vaccinated mice showed no efficacy in suppression of the paralysis endpoint (FIG. 11). In contrast, PrC-210 was found to be effective at suppressing paralysis (see FIG. 7).

[0324] Example 7. Plasma pharmacokinetics of PrC-210 in healthy pigs

[0325] The plasma pharmacokinetics of PrC-210 was evaluated in healthy pigs following the regimen shown in FIG. 12. Catheterized ~ 50 kg pigs received a single IV bolus injection of PrC-210 in isotonic saline at time 0, and 4 ml blood samples were drawn at the indicated times through two hours. For most pigs, additional blood samples were drawn at times up to 7 days later to enable CBC and blood chemistry assessments. After LC-MS assay of the PrC-210-NEM conjugate in separated plasmas, the following was observed: i) plasma levels of PrC-210 were typically reduced to levels not statistically different than plasma background by 30 min post-injection; and ii) plasma PrC-210 concentrations in female pigs that received the same 5.02 mg / kg IV dose as males were higher (45000 fmol in females vs 30000 fmols in males). This phenomenon was seen in virtually all male / female dose comparisons (FIGs. 13A and 13B).

[0326] In FIG. 14, plasma PrC-210 concentrations versus time post-injection were plotted for each of the shown male and female pigs, and AUC values were calculated from the plots. Best-fit curves for the two data sets show: i) clear dose vs. AUC linearity over a 12-fold (2.5 mg / kg - 29.6 mg / kg) increase in administered IV PrC-210 dose to male pigs; and ii) from best-fit curves, at an equal PrC-210 dose of 5.02 mg / kg in male and female pigs, the AUC for females was 15% greater.

[0327] Example 8. Toxicokinetics of PrC-210 in healthy pigs

[0328] The toxicokinetics of PrC-210 was evaluated in healthy pigs following the regimen shown in FIG.

[0329] 12. All pigs were monitored with video camera for at least 15-20 min following PrC-210 administration, and then continually monitored by observation until there were no longer any visible toxicities. In a male pig (Pig 2.1) that arbitrarily received a dose of 29.6 mg / kg PrC-210, which was 6.75-fold higher than the extrapolated “toxic dose” (i.e., 4.40 mg / kg), the first emesis event was observed 10 min after the IV bolus of PrC-210. There were 14 more emesis events in the following 50 min, roughly equally spaced in time (FIG. 15A). Following these emesis events, the pig appeared to be normal in its behavior and consumed both water and corn meal when it was offered. The next day, the same experiment was repeated in a new male pig (Pig 3.1) and encountered virtually identical results with 13 emesis events in a 60 min period.PATENT

[0330] ATTORNEY DOCKET NO: 51707-007W02

[0331] Subsequently, a third male pig was dosed with 8.6 mg / kg and as shown in FIG. 15B, this pig had two emesis events in the 60 min observation period. These toxic events were extrapolated back to the X-axis, which yielded a NOAEL dose of 5.02 mg / kg in the male mice. This extrapolated value of 5.02 is 14% higher than the predicted NOAEL dose (4.40 mg / kg) based solely upon extrapolation from the mouse MTD value.

[0332] Example 9. Blood chemistry of healthy pigs after PrC-210 administration

[0333] A portion of each timepoint blood draw was used to perform complete blood counts to determine what effect, if any, the single IV bolus dose of PrC-210 had upon blood cell populations in healthy pigs. FIG. 16 summarizes results in which each blood cell component was measured and quantified at the indicated time points after the single IV bolus PrC-210 dose. Values in FIG. 16 represent the mean of at least 3 pigs assessed at the indicated timepoints and PrC-210 doses in both male and female pigs. The simplest assessment of the data shows no significant changes in any of the blood cell components at up to seven days following the NOAEL dose of PrC-210.

[0334] The data in FIG. 17 show blood chemistry components in at least three pigs at each indicated PrC-210 dose and time point after the single IV bolus PrC-210 dose. The most obvious observation is that there are no discernible changes in blood chemistry parameters covering kidney, bone marrow, and liver function that are changed in the PrC-210 treatment groups, even including the pigs that received 5.9 x the pig NOAEL dose of PrC-210.

[0335] The most noteworthy aspect of both the blood CBC (Complete Blood Counts) and blood metabolic panels is that there is nothing discernibly changed (i.e., no discernible toxicities) in any of the PrC-210 IV dose groups when compared to untreated control pigs. The blood chemistry panel is designed to screen for damage markers in each critical organ in mammals, and there are no discernible changes.

[0336] Example 10. Pig tissue histology after administration of PrC-210

[0337] FIG. 18 shows organ histology sections from critical organs isolated from pigs that received no PrC-210 (Control) and those that received 5.9 X the pig NOAEL dose of PrC-210. Every pig was euthanized 7 days following the single PrC-210 IV dose, and veterinary pathologists performed a standard necropsy of each pig, and organ tissue was fixed in 10% formalin for histology. The 10X histology images in FIG. 18 show no discernible difference from tissue images from pigs that received the control vs. a pig that received 29.6 mg / kg PrC-210 as an IV bolus dose.

[0338] Example 11. Administration of PrC-210 in human subjects

[0339] The pharmaceutical composition of PrC-210, ora pharmaceutically acceptable salt thereof, is administered intravenously or orally to a human subject with MS, including subjects with relapsingremitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), and progressive relapsing multiple sclerosis (PRMS).

[0340] Each intravenous administration delivers about 1.2 to about 3.5 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof. For example, 1.2, 1.3, 1.4, 1.5, 1.5, 1.7, 1.8, 1.9, 2.0, 2.1 , 2.2, 2.3, 2.4, or 2.5 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof is intravenouslyPATENT

[0341] ATTORNEY DOCKET NO: 51707-007W02

[0342] administered to the subject. The human subject is treated once a day (QD), twice a day (BID), three times a day (TID), four times a day (QID), once every other day (Q2D), once every third day (Q3D), once every fourth day, once every fifth day, once every sixth day, once a week, twice a week, once every two weeks, once every three weeks, once a month, or any dosing schedule as needed.

[0343] Each oral administration delivers about 3.5 to about 35 mg / kg (e.g., about 3.5 to 10, about 5 to 10, about 5 to 15, about 10 to 15, about 10 to 20, about 15 to 25, about 15 to 30, about 20 to 30, about 25 to 30, about 25 to 35, about 30 to 35, 8.5±5, 10±5, 15±5, 20±5, or 30±5 mg / kg) of PrC-210, or a pharmaceutically acceptable salt thereof. For example, 3.5, 4±0.5, 5±0.5, 6±0.5, 7±0.5, 8±0.5, 9±0.5, 10±0.5, 11±0.5, 12±0.5, 13±0.5, 14±0.5, 15±0.5, 16±0.5, 17±0.5, 18±0.5, 19±0.5, 20±0.5, 21±0.5, 22±0.5, 23±0.5, 24±0.5, 25±0.5, 26±0.5, 27±0.5, 28±0.5, 29±0.5, 30±0.5, 31 ±0.5, 32±0.5, 33±0.5, 34±0.5, or 35 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof is orally administered to the subject. The human subject is treated once a day (QD), twice a day (BID), three times a day (TID), four times a day (QID), once every other day (Q2D), once every third day (Q3D), once every fourth day, once every fifth day, once every sixth day, once a week, twice a week, once every two weeks, once every three weeks, once a month, or any dosing schedule as needed.

[0344] For subjects experiencing the quiescent period, a flexible dosing regimen is evaluated in which, during the quiescent period, PrC-210, or a pharmaceutically acceptable salt thereof, is intravenously administering to the subject an amount of about 0.02 to about 0.40 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof and during the non-quiescent period, intravenously administering to the subject about 0.15 to about 1 .21 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof. Further, administering the PrC-210, or a pharmaceutically acceptable salt thereof, only during the quiescent period, an amount between about 0.15 to about 1.21 mg / kg is accessed.

[0345] Additionally, administering the PrC-210, or a pharmaceutically acceptable salt thereof, only during the non-quiescent period, an amount between about 0.02 to about 0.40 mg / kg is assessed. For subjects experiencing the quiescent period, a flexible dosing regimen is evaluated in which, during the quiescent period, PrC-210, or a pharmaceutically acceptable salt thereof, is orally administering to the subject in an amount of about 265 to about 4265 mg / kg, and during the non-quiescent period, orally administering to the subject about 265 to about 4265 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof. Further, administrating the PrC-210, or a pharmaceutically acceptable salt thereof, only during the quiescent period, an amount between about 0.15 to about 6.0 mg / kg is assessed. Additionally, administering the PrC-210, or a pharmaceutically acceptable salt thereof, only during the non-quiescent period, an amount between about 265 to about 4265 mg / kg is assessed.

[0346] For subjects experiencing flare-ups, PrC-210, or a pharmaceutically acceptable salt thereof, is orally administering to the subject in an amount of about 265 to about 4265 mg / kg.

[0347] For subjects experiencing flare-ups, PrC-210, or a pharmaceutically acceptable salt thereof, is intravenously administering to the subject about 6 to about 125 mg.

[0348] Example 12. Temporal reductive stress response to PrC-210 in 11 Gy IR-treated mice Compared to mice treated with PrC-210 30 minutes after irradiation, those treated prior to irradiation exhibited significantly higher free radical levels, despite receiving the same radiation dose and PrC-210 amount (FIG. 20). This striking difference may be due to excessive antioxidant scavengingPATENT

[0349] ATTORNEY DOCKET NO: 51707-007W02

[0350] before irradiation, which likely suppressed redox levels below the physiological redox window, thereby inducing a reductive stress response. In contrast, animals treated with 0.5 MTD PrC-21030 minutes after irradiation did not experience this initial redox suppression and instead showed a more typical free radical profile. The pre-treated group appears to have undergone an additional surge of free radicals, potentially driven by an endogenous response to reductive stress.

[0351] Example 13. Administration of PrC-210 to mice pre- and post-radiation

[0352] In the setting of acute irradiation injury (8.6 Gy), the administration of a single dose of PrC-210, a small molecule aminothiol ROS scavenger, before irradiation exposure was able to suppress ROS levels to background levels over the course of one week. With non-treated irradiated mice showing pronounced ROS peaks at 12 hr and 6 days post irradiation exposure, illustrating the fluctuating ROS levels during the acute stage of the condition (see FIG. 21 and FIG. 22).

[0353] As in Acute Conditions ROS level decline with time it is important to note that PrC-210’s treatment dose has to be accordingly reduced to prevent reductive stress. This is due to the observation that too high doses of PrC-210 lower ROS levels below the homeostatic redox state, which activates a cascade of both enzymatic and transcriptional processes that elevate the production of ROS to restore the cellular redox balance.

[0354] This was studied by chemiluminescent quantification the ROS levels in mice that were either treated with a higher dose (0.5 MTD) ora lower dose of PrC-210 (0.1 MTD) either before receiving 1 Gy of irradiation or 30 minutes after. While the mice that received Prc-21030 minutes before being irradiated should show lower ROS levels as they were able to suppress the irradiation-induced ROS peak, they paradoxically showed equal ROS levels to the non-treated group, suggesting a reductive stress reaction in which the high dose of PrC-210 reduced cellular ROS levels below the homeostatic redox state, consequentially causing an endogenously driven increase in ROS production. In comparison, the high dose of PrC-210 (0.5 MTD) administered to mice 30 minutes post 1Gy irradiation, showed a reduction in ROS levels which stayed above homeostatic background levels due to IR induced elevation in ROS levels. Further evidence for a ROS-level informed treatment dose, comes from the observation that mice pretreated before irradiation or treated after irradiation showed equally lowered levels of ROS compared to non-treated animals, indicating an absence of reductive stress.

[0355] Other Embodiments

[0356] Various modifications and variations of the described compositions, methods, and uses of the invention will be apparent to those skilled in the art without departing from the scope and spirit of the invention. Although the invention has been described in connection with specific embodiments, it should be understood that the invention as claimed should not be unduly limited to such specific embodiments. Indeed, various modifications of the described modes for carrying out the invention that are obvious to those skilled in the art are intended to be within the scope of the invention.

[0357] Other embodiments are in the claims.

Claims

PATENTATTORNEY DOCKET NO: 51707-007W02CLAIMS1. A method of treating a subject with prodromal multiple sclerosis, said method comprising administering to the subject an effective amount of a compound of PrC-210,HS.H HPrC-210or a pharmaceutically acceptable salt thereof.

2. The method of claim 1 , wherein the treatment slows the progression of multiple sclerosis in the subject.

3. A method of treating a subject with relapsing-remitting multiple sclerosis (RRMS), said method comprising administering to the subject an effective amount of a compound of PrC-210,HS.H HPrC-210or a pharmaceutically acceptable salt thereof.

4. The method of claim 3, wherein the subject is experiencing a relapse.

5. The method of claim 4, wherein the relapse is reduced in severity or duration.

6. The method of claim 3, wherein the subject is experiencing remission.

7. The method of claim 6, wherein the remission is extended in duration.

8. A method of treating a subject with primary progressive multiple sclerosis (PPMS), said method comprising administering to the subject an effective amount of a compound of PrC-210,HS.H HPrC-210or a pharmaceutically acceptable salt thereof.

9. The method of claim 8, wherein the subject’s symptoms are reduced in severity or duration.PATENTATTORNEY DOCKET NO: 51707-007W0210. A method of treating a subject with secondary progressive multiple sclerosis (SPMS), said method comprising administering to the subject an effective amount of a compound of PrC-210,HS.H HPrC-210or a pharmaceutically acceptable salt thereof.

11. The method of claim 10, wherein the subject is experiencing a relapse.

12. The method of claim 10, wherein the relapse is reduced in severity or duration.

13. The method of claim 10, wherein the subject is experiencing remission.

14. The method of claim 10, wherein the remission is extended in duration.

15. A method of treating a subject with progressive relapsing multiple sclerosis (PRMS), said method comprising administering to the subject an effective amount of a compound of PrC-210,HS.H HPrC-210or a pharmaceutically acceptable salt thereof.

16. The method of claim 15, wherein the subject’s symptoms are reduced in severity or duration.

17. A method of suppressing demyelination in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound of PrC-210,HS.H HPrC-210or a pharmaceutically acceptable salt thereof.

18. The method of claim 17, wherein the subject has prodromal multiple sclerosis or multiple sclerosis.

19. The method of claim 17 or 18, wherein the suppressing slows the progression of prodromal multiple sclerosis or multiple sclerosis in the subject.PATENTATTORNEY DOCKET NO: 51707-007W0220. A method of reducing the frequency or severity of a flare-up period or a relapse period in a subject suffering from multiple sclerosis, said method comprising administering to the subject an effective amount of a compound of PrC-210,HS.H HPrC-210or a pharmaceutically acceptable salt thereof.

21. The method of claim 20, wherein PrC-210 is administered at the onset of flare-up or relapse symptoms.

22. The method of claim 20 or 21, wherein the administration of PrC-210 reduces fatigue, weakness, numbness, vision changes, balance problems, bladder issues, or cognitive difficulties in the subject.

23. The method of any one of claims 1 to 22, wherein PrC-210, ora pharmaceutically acceptable salt thereof, is in a pharmaceutical composition comprising a pharmaceutically acceptable excipient.

24. The method of any one of claims 1 to 22, wherein PrC-210, ora pharmaceutically acceptable salt thereof, or the pharmaceutical composition of claim 23, is administered orally, subcutaneously,25. A method of treating multiple sclerosis in a subject comprising: (i) during the quiescent period, intravenously administering to the subject an amount of about 0.02 to about 0.40 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, and (ii) during the non-quiescent period, intravenously administering to the subject about 0.15 to about 1.21 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof.

26. A method of treating multiple sclerosis in a subject comprising intravenously administering to the subject an amount of about 0.02 to about 0.40 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, during the quiescent period.

27. A method of treating multiple sclerosis in a subject comprising intravenously administering to the subject about 0.15 to about 1.21 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, during the non-quiescent period.

28. A method of treating multiple sclerosis in a subject comprising: (i) during the quiescent period, orally administering to the subject an amount of about 0.15 to about 6.0 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, and (ii) during the non-quiescent period, orally administering to the subject about 265 to about 4265 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof.PATENTATTORNEY DOCKET NO: 51707-007W0229. A method of treating multiple sclerosis in a subject comprising orally administering to the subject an amount of about 0.15 to about 6.0 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof, during the quiescent period.

30. A method of reducing flare-up severity in a subject with multiple sclerosis comprising orally administering to the subject about 265 to about 4265 mg / kg PrC-210, or a pharmaceutically acceptable salt thereof, during the non-quiescent period.

31. A method of treating multiple sclerosis in a subject comprising: (i) during the quiescent period, intravenously administering to the subject an amount of about 1 to about 40 mg of PrC-210, or a pharmaceutically acceptable salt thereof, and (ii) during the non-quiescent period, intravenously administering to the subject about 6 to about 125 mg of PrC-210, or a pharmaceutically acceptable salt thereof.

32. A method of treating multiple sclerosis in a subject comprising intravenously administering to the subject an amount of about 1 to about 40 mg of PrC-210, or a pharmaceutically acceptable salt thereof, during the quiescent period.

33. A method of reducing flare-up severity in a subject with multiple sclerosis comprising intravenously administering to the subject about 6 to about 125 mg of PrC-210, or a pharmaceutically acceptable salt thereof, during the non-quiescent period.

34. A method of treating multiple sclerosis in a subject comprising: (i) during the quiescent period, orally administering to the subject an amount of about 6 to about 780 mg of PrC-210, or a pharmaceutically acceptable salt thereof, and (ii) during the non-quiescent period, orally administering to the subject about 60 to about 3900 mg of PrC-210, or a pharmaceutically acceptable salt thereof.

35. A method of treating multiple sclerosis in a subject comprising orally administering to the subject an amount of about 35 to about 1420 mg of PrC-210, ora pharmaceutically acceptable salt thereof, during the quiescent period.

36. A method of reducing flare-up severity in a subject with multiple sclerosis comprising orally administering to the subject about 265 to about 4265 mg PrC-210, or a pharmaceutically acceptable salt thereof, during the non-quiescent period.

37. The method of any one of claims 25 to 36, wherein the subject has relapsing-remitting multiple sclerosis (RRMS), primary progressive multiple sclerosis (PPMS), secondary progressive multiple sclerosis (SPMS), or progressive relapsing multiple sclerosis (PRMS).PATENTATTORNEY DOCKET NO: 51707-007W0238. The method of any one of claims 25 to 37, wherein the subject is experiences relapses and remissions, and wherein the relapse is reduced in severity or duration; or the remission is extended in duration.

39. A method of treating a subject with prodromal multiple sclerosis comprising administering to the subject an effective amount of a compound of PrC-210, or a pharmaceutically acceptable salt thereof, and wherein:a. the method comprises intravenously administering to the subject an amount of about 0.02 to about 0.4mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof;b. the method comprises orally administering to the subject an amount of about 0.71 to about 14.21 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof;c. the method comprises intravenously administering to the subject an amount of about 1 to about 40 mg of PrC-210, or a pharmaceutically acceptable salt thereof; ord. the method comprises orally administering to the subject an amount of about 35 to about 1420 mg of PrC-210, or a pharmaceutically acceptable salt thereof.

40. A method of suppressing demyelination in a subject in need thereof, said method comprising administering to the subject an effective amount of a compound of PrC-210, or a pharmaceutically acceptable salt thereof, and wherein:a. the method comprises intravenously administering to the subject an amount of about 0.15 to about 1.21 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof;b. the method comprises orally administering to the subject an amount of about 265 to about 4265 mg / kg of PrC-210, or a pharmaceutically acceptable salt thereof;c. the method comprises intravenously administering to the subject an amount of about 6 to about 125 mg of PrC-210, or a pharmaceutically acceptable salt thereof; ord. the method comprises orally administering to the subject an amount of about 265 to about 4265 mg of PrC-210, or a pharmaceutically acceptable salt thereof.

41. The method of any one of claims 25 to 40, wherein the administering is from the amount daily to the amount weekly.

42. A method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the prodromal stage, the method comprising intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about .02 to about 0.40 mg / kg.

43. A method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the advanced stage, the method comprising intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 0.1 to about 1.21 mg / kg.PATENTATTORNEY DOCKET NO: 51707-007W0244. A method of treating Multiple Sclerosis in a subject in need thereof, the method comprising:(i) intravenously administering to the subject in the prodromal stage of Multiple Sclerosis the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about .02 to about 0.40 mg / kg; and(ii) after Multiple Sclerosis is in the advanced stage in the subject, intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 0.1 to about 1.21 mg / kg45. A method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the prodromal stage, the method comprising intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from about 1 to about 40 mg.

46. The method of embodiment 45, comprising intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 1 to 10 mg.

47. The method of embodiment 45, comprising intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 5 to 20 mg.

48. The method of embodiment 45, comprising intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 15 to 30 mg.

49. The method of embodiment 45, comprising intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 25 to 40 mg.

50. A method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the advanced stage, the method comprising intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from about 5 to about 121 mg.

51. The method of embodiments 50, comprising intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 5 to 20 mg.

52. The method of embodiments 50, comprising intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 10 to 40 mg.

53. The method of embodiments 50, comprising intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 20 to 75 mg.

54. The method of embodiments 50, comprising intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 30 to 100 mg.PATENTATTORNEY DOCKET NO: 51707-007W0255. The method of embodiments 50, comprising intravenously administering to the subject the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from 40 to 121 mg.

56. A method of treating Multiple Sclerosis in a subject in need thereof, the method comprising:(i) intravenously administering to the subject in the prodromal stage of Multiple Sclerosis the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 1 to about 40 mg; and(ii) after Multiple Sclerosis is in the advanced stage in the subject, intravenously administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 5 to about 121 mg.

57. The method of embodiment 56, wherein the method comprises:(i) intravenously administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 1 to 10 mg; and(ii) intravenously administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 10 to 40 mg.

58. The method of embodiment 56, wherein the method comprises:(i) intravenously administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 5 to 20 mg; and(ii) intravenously administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 20 to 75 mg.

59. The method of embodiment 56, wherein the method comprises:(i) intravenously administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 15 to 30 mg; and(ii) intravenously administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 30 to 100 mg.

60. The method of embodiment 56, wherein the method comprises:(i) intravenously administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 25 to 40 mg; and(ii) intravenously administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 40 to 121 mg.

61. A method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the prodromal stage, the method comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 0.71 to about 14.21 mg / kg.PATENTATTORNEY DOCKET NO: 51707-007W0262. A method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the advanced stage, the method comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 3.55 to about 42.63 mg / kg.

63. A method of treating Multiple Sclerosis in a subject in need thereof, the method comprising:(i) orally administering to the subject in the prodromal stage of Multiple Sclerosis the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from about 0.71 to about 14.21 mg / kg; and(ii) after Multiple Sclerosis is in the advanced stage in the subject, orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 3.55 to about 42.63 mg / kg.

64. A method of treating Multiple Sclerosis in a subject in need thereof, wherein the progressive neurodegenerative disease is in the prodromal stage, the method comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 35 to about 1420 mg.

65. The method of embodiment 64 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 35 to 175 mg.

66. The method of embodiment 64 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 175 to 315 mg.

67. The method of embodiment 64 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 315 to 500 mg.

68. The method of embodiment 64 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 200 to 675 mg.

69. The method of embodiment 64 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 900 mg.

70. The method of embodiment 64 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 1100 mg.

71. The method of embodiment 64 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 800 to 1420 mg.

72. A method of treating Multiple Sclerosis in a subject in need thereof, wherein Multiple Sclerosis is in the advanced stage, the method comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 175 to about 4265 mg.PATENTATTORNEY DOCKET NO: 51707-007W0273. The method of embodiment 72 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 175 to 1200 mg.

74. The method of embodiment 72 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 315 to 1350 mg.

75. The method of embodiment 72 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 500 to 1500 mg.

76. The method of embodiment 72 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 2000 mg.

77. The method of embodiment 72 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 900 to 2100 mg.

78. The method of embodiment 72 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 1100 to 4000 mg.

79. The method of embodiment 72 comprising orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 1420 to 4265 mg.

80. A method of treating Multiple Sclerosis in a subject in need thereof, the method comprising:(i) orally administering to the subject in the prodromal stage of Multiple Sclerosis the compound PrC-210, ora pharmaceutically acceptable salt thereof, in an amount of from about 35 to about 1420 mg; and(ii) after Multiple Sclerosis is in the advanced stage in the subject, orally administering to the subject the compound PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from about 175 to about 4265 mg.

81. The method of embodiment 80, the method comprises:(i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 35 to 175 mg; and(ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 175 to 1200 mg.

82. The method of embodiment 80, the method comprises:(i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 175 to 315 mg; and(ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 315 to 1350 mg.PATENTATTORNEY DOCKET NO: 51707-007W0283. The method of embodiment 80, the method comprises:(i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 315 to 500 mg; and(ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 500 to 1500 mg.

84. The method of embodiment 80, the method comprises:(i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 200 to 675 mg; and(ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 2000 mg.

85. The method of embodiment 80, the method comprises:(i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 900 mg; and(ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 900 to 2100 mg.

86. The method of embodiment 80, the method comprises:(i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 675 to 1100 mg; and(ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 1100 to 4000 mg.

87. The method of embodiment 80, the method comprises:(i) orally administering to the subject with the prodromal stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 800 to 1420 mg; and(ii) orally administering to the subject with the advanced stage of the disease PrC-210, or a pharmaceutically acceptable salt thereof, in an amount of from 1420 to 4265 mg.